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Head and neck cancer (HNSCC) affects 650,000 people annually. Laryngeal cancer 
(LSCC) and oropharyngeal cancer (OPSCC) are amongst the commonest sub-types.  
 
For other cancers e.g. breast cancer, personalised treatments based on tumour markers 
have improved patient survival. With the exception of human papilloma virus (HPV); 
there are no clinically utilised biomarkers in HNSCC.  
 
Insulin growth factor receptor 1 (IGF-1R) and HPV are promising molecular markers in 
LSCC and OPSCC respectively. This thesis investigates the use of IGF-1R as a marker 




• To assess IGF-1R as a marker of radiotherapy resistance in LSCC. 




Immunohistochemistry (IHC) was used to compare IGF-1R levels between patients 
with LSCC achieving long-term remission and experiencing recurrence after 
radiotherapy.  LSCC cells were used to create and interrogate an in vitro model of 
radiation resistance.   
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Following the completion of a systematic review on HPV testing in OPSCC, a 
diagnostic accuracy study was performed to determine the sensitivity and specificity of 
saliva testing for HPV in OPSCC.  
 
Results: 
IGF-1R levels are higher in radioresistant LSCC and increase following radiotherapy. 
IGF-1R inhibition appears to be more effective at limiting cell survival in cells with 
IGF-1R overexpression.  
 
The sensitivity and specificity of saliva testing when compared to p16 IHC and HPV 
DNA in situ hybridisation is 72.2% and 90%.  
 
Conclusions: 
Elevated IGF-1R appears to associate with previous radiotherapy and radiotherapy 
resistance in LSCC. Treatments accounting for IGF-1R status, or molecular therapies 
targeting this receptor, may have merit in patients whose tumours overexpress IGF-1R. 
 
Saliva testing for HPV is a promising alternative to p16 IHC performed on tumour 
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Introduction: Molecular Targets in Head and Neck Cancer 
Head and neck squamous cell carcinoma (HNSCC) is the 6th commonest cancer 
worldwide affecting 650,000 people each year [1]. Two of the most commonly affected 
sites are the larynx and oropharynx with 2,315 [2] and 2,303 [3] new cases diagnosed 
each year in the United Kingdom (UK). Both laryngeal squamous cell carcinoma 
(LSCC) and oropharyngeal squamous cell carcinoma (OPSCC) are treated with surgery 
or chemoradiotherapy.  
 
Research into the field of personalised medicine has shown that molecularly distinct 
subtypes of common cancers exist. These findings have had implications on prevention, 
diagnosis, prognosis and treatment in numerous solid organ tumours [4].  
 
Examples include the discovery that mutations in the BRCA gene give a 45-65% chance 
of developing breast cancer by the age of 70. This has led many patients to opt for 
prophylactic mastectomy or hormone suppression to prevent breast cancer. More 
recently the presence of BRCA1/2 has also shown the ability to predict response to anti-
PARP therapy in ovarian cancer [5]. In metastatic or non-resectable malignant 
melanoma the introduction of Vemurafenib in patients with an activating mutation in 
the BRAF oncogene has led to increases in overall and progression free survival of 3.9 
months and 5.3 months respectively in comparison to standard treatments [6].    
 
Treatments for HNSCC have not kept pace; there is a need to bring personalised 
medicine into the care of these patients. For LSCC and OPSCC the choice, number and 
regime of treatments offered is guided by disease stage, patient co-morbidity, patient 
choice and clinical expertise. It is only very recently that the presence of human 
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papilloma virus (HPV) has shown a potential role in the management of patients with 
OPSCC [7] [8].  
 
Laryngeal Cancer 
Laryngeal squamous cell carcinoma (LSCC) affects four times as many men as women 
and is caused by tobacco smoking and alcohol consumption, these have a synergistic 
effect on the onset of disease [7]. The clinical presentation of LSCC depends on the 
sub-site of the larynx affected. Glottic disease, which affects the true vocal cords 
typically presents early with patients experiencing a hoarse voice.  Subglottic or 
supraglottic disease usually presents later with dysphagia, odynophagia, neck masses or 
rarely airway obstruction.  
 
In the UK there has been an approximate 20% reduction in new diagnoses and deaths 
from laryngeal cancer over the past 2 decades [7]. These observations may relate to the 
success of smoking cessation interventions [9] or earlier diagnosis through increased 
clinician awareness and earlier specialist referral [10].  
 
There are no clinically utilised biomarkers for LSCC and when compared to other solid 
organ tumours e.g. breast, lung and prostate there have been relatively few new 
treatments to improve survival [11]. Instead there has been a focus on organ 
preservation and function through targeted radiotherapy e.g. intensity-modulated 
radiotherapy and minimal access surgery e.g. transoral laser microsurgery [12].  
 
There is clearly a need for new molecular therapies and biomarkers for LSCC and in the 
age of personalized medicine, agents targeting the epidermal growth factor receptor 
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(EGFR) appear promising for both [13]. EGFR is overexpressed in more than 80% of 
HNSCCs and increased expression is associated with poorer prognosis, increased loco-
regional recurrence and increased resistance to radiotherapy [14,15]. A better 
understanding of how EGFR interacts with other receptor tyrosine kinases (RTKs) e.g. 
IGF-1R may provide the key to solving the challenges of treatment resistance.  
 
Clinically the only new agent to gain National Institute for Health and Care Excellence 
(NICE) approval for LSCC in the past decade is Cetuximab [16]. In randomised 
controlled trials, this monoclonal antibody to EGFR, when combined with radiotherapy 
vs. radiotherapy alone has shown improved local-regional control and 5 year survival of 
24.4 months and 45.6% vs. 14.9 months and 36.4% respectively [17,18]. Unfortunately 
there is a short-term response to treatment due to acquired resistance thereby limiting its 
clinical application [19].   
 
Colorectal cancers also overexpress EGFR and were initially thought to develop 
treatment resistance to Cetuximab. The discovery that only colorectal tumours 
expressing wild-type KRAS responded to this treatment led to the licensing of 
Cetuximab as a new treatment in this group of patients. We now know that Cetuximab 
improves quality of life and doubles overall and progression free survival when 
compared to supportive care only for patients with wild type KRAS and colorectal 
cancer. As a result KRAS testing is now routine for patients with colorectal cancer [20].  
 
As with other solid organ tumours it is hoped that EGFR and associated receptor 
tyrosine kinases e.g. IGF-1R may prove to be useful biomarkers or molecular targets for 
future treatment regimes in LSCC. Better appreciation of their interaction and 
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expression in vitro and in vivo may help to identify new sub-groups of patients likely to 
respond to or fail conventional treatment regimes.   
 
Oropharyngeal Cancer 
Oropharyngeal squamous cell carcinoma (OPSCC) affects the palatine tonsils or tongue 
base and is conventionally associated with alcohol consumption and smoking. More 
recently a new sub-type has emerged associated with human papilloma virus (HPV) in 
younger healthier non-smokers. Despite a reduction in smoking and alcohol 
consumption, the UK incidence of OPSCC doubled between 1990 and 2006 and then 
again between 2006 and 2010 [8]. The exponential rise was attributed to HPV 
associated OPSCC (HPV+ve). HPV+ve OPSCC is set to overtake the incidence of HPV 
associated cervical cancer by 2020 [21] and is a major health epidemic in the western 
world [22].   
 
Patients with OPSCC can remain asymptomatic for prolonged periods before presenting 
with otalgia, dysphagia, odynophagia, neck masses and rarely breathing difficulties. The 
prognosis and response to treatment for conventional or HPV negative (HPV-ve) 
OPSCC is very different to HPV+ve disease. Local-regional treatment failure and 5 
year survival is reported at 13% and 82% for HPV+ve OPSCC whilst it is 42% and 35% 
in HPV-ve disease [23].  
 
HPV is the only biomarker of clinical relevance for patients with HNSCC but is only 
clinically useful for patients with OPSCC. The presence of HPV can predict prognosis, 
guide treatment decisions and determine suitability for entry into de-escalation clinical 
trials [24].  
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HPV testing is considered the standard of care for patients with OPSCC and is 
performed using polymerase chain reaction (PCR), DNA in situ hybridisation (ISH) and 
p16 immunohistochemistry (IHC) [25]. All of these tests are limited by the need for 
invasive surgical biopsies that take time to collect and are associated with morbidity. 
 
The ideal test for HPV in patients with OPSCC would be non-invasive, economical and 
taken at the point of first patient contact. It could form part of screening/monitoring 
programmes for individuals with OPSCC and be performed by general practitioners at 
the time of specialist referral. This might shorten time to diagnosis and treatment; 
improve patient satisfaction and overall mortality. Recent tests have emerged with the 
potential to use saliva to detect oropharyngeal HPV, however, they are yet to be 
validated in the context of OPSCC [26]. If proven accurate saliva testing could replace 














Chapter 1: Insulin Like Growth Factor Receptor 1 (IGF-1R) and Radiotherapy 




Salvage surgery is the only option for radiotherapy failure in laryngeal squamous cell 
carcinoma (LSCC), but is associated with high morbidity. There is a need to identify 
biomarkers of radio resistance, to inform treatment decisions. Epidermal growth factor 
receptor (EGFR) associates with radiotherapy resistance in head and neck cancer 
(HNSCC), and insulin-like growth factor receptor type 1 (IGF-1R) correlates with 
radiotherapy resistance in other tumour types. We recently reported that IGF-1R 
associates with advanced T-stage, HPV negativity and adverse survival in HNSCC.  
Here, we evaluated IGF-1R and EGFR in predicting radiotherapy failure in LSCC.  
 
Aims: 
To assess IGF-1R and EGFR expression in patients treated with radiotherapy for LSCC 
and compare receptor levels in patients experiencing radiotherapy without known 
recurrence vs. those experiencing radiotherapy failure.  
 
Methods:  
We scored membrane, cytoplasmic and total (membrane plus cytoplasmic) EGFR and 
IGF-1R using immunohistochemistry on biopsies and salvage laryngectomies from 63 
LSCC patients, including 41 treated with radiotherapy (23 radiotherapy without known 




IGF-1R scores were higher in the biopsies of the radiotherapy failure group, with scores 
in the membrane of 3.07 vs. 1.0 (p=0.004), cytoplasm 3.36 vs. 2.17 (p=0.18) and total 
IGF-1R 6.43 vs. 3.17 (p=0.01) compared with those receiving radiotherapy without 
known recurrence. IGF-1R expression was positively associated with increasing tumour 
size and increased following radiotherapy whilst EGFR expression remained static 
following radiotherapy.  EGFR scores did not correlate with radiotherapy outcomes. 
Patients undergoing primary laryngectomy had higher T and N stage (p<0.05) and 
higher tumour IGF-1R (8.3 vs. 3.17, p=0.02) than those experiencing radiotherapy 
without known recurrence 
 
Conclusions:  
These results suggest that IGF-1R associates with radiotherapy resistance, higher T-
stage and is up regulated following radiotherapy in LSCC. Treatments accounting for 
IGF-1R status, or molecular therapies targeting this receptor, may have merit in patients 












Over the past 20 years, unlike other solid organ tumours, 5-year survival from laryngeal 
squamous cell carcinoma (LSCC) in the US has remained relatively unchanged from 
66% to 63% [27]. Whilst large US epidemiological studies have shown a declining 
incidence of 2.3% per year over the past decade[28], there will still be 13,400 new cases 
of LSCC diagnosed in 2016 with 3600 deaths as a direct consequence of the disease 
[29]. In the UK, where LSCC accounts for 1% of all cancers in men and 0.3% of 
cancers in women, there has been a 20% reduction in incidence and mortality over the 
past 2 decades [30]. These changes may be attributable to the success of smoking 
cessation interventions [9] or earlier diagnosis through increased clinician awareness 
and earlier specialist referral [10]. In the UK the overall 5 year survival is estimated at 
65% [31] with approximately 2400 new cases and 800 deaths attributable to LSCC 
annually [30]. This makes LSCC one of the largest subgroups of head and neck 
squamous cell carcinoma (HNSCC).  
 
Treatment for LSCC utilises a multidisciplinary team (MDT) approach, taking into 
consideration the TNM classification, patient performance status, patient preference and 
treatment objectives, whether palliative or curative. When curative treatment is 
undertaken for early stage disease (T1/2), options include radiotherapy, trans-oral laser 
microsurgery (TLM) or partial open laryngeal surgery. Given the absence of 
comparative randomised controlled trials there is insufficient evidence to determine the 
most effective option [32]. In the UK patients with early LSCC are usually treated with 
either radiotherapy with salvage laryngectomy reserved for cases of recurrence, or TLM 
with further surgery or radiotherapy if required [30].  Five-year survival and local 
control rates with radiotherapy and TLM are similar at approximately 80% [33,34].  
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Treatment regimes for advanced LSCC are controversial, with some authors advocating 
primary partial laryngeal surgery or total laryngectomy followed by radiotherapy 
[35,27]. Concurrent chemo-radiotherapy is widely used as the initial treatment modality 
aimed at preserving laryngeal function. This choice is largely influenced by the findings 
of the landmark Veterans Affairs (VA) [36] and subsequent Radiation Therapy 
Oncology Group (RTOG) [37] studies published in 1991 and 2003 respectively. The 
VA study demonstrated equivalent survival of 68% for patients with advanced LSCC 
treated with both induction chemotherapy and radiotherapy or laryngectomy followed 
by adjuvant radiotherapy. There was a significantly lower rate of salvage laryngectomy 
in T3 vs. T4 disease (29% vs. 56% p=0.001)[36]. The RTOG study found concurrent 
chemo-radiotherapy was superior to both induction chemotherapy with radiotherapy and 
radiotherapy alone in preserving laryngeal function (88% vs. 75% vs. 70%) [37]. As a 
consequence of these findings patients with T3/T4 LSCC traditionally treated with 
laryngectomy are now frequently offered concurrent chemo-radiotherapy. Exceptions 
include cases where there is tumour invasion through cartilage into the soft tissues of 
the neck or when chemotherapy is contraindicated, for example in those over 70 years 
old, or with hepatic or renal impairment [30].  
 
The overall results of laryngeal preservation for advanced stage LSCC have meant that 
the rates for primary total laryngectomy have declined faster than the incidence of 
LSCC, consistent with a trend towards nonsurgical treatment in the form of concurrent 
chemo-radiotherapy [38].  
 
Although non-surgical treatments for laryngeal cancer are considered effective, 
treatment failure is inevitable in a proportion of individuals [39]. In early LSCC, 
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radiotherapy failure rates have been reported to be as high as 9%-21% in T1 and 28%-
37% in T2 glottic [40,41] and 24%-30% in T1 and 25%-45% in T2 supraglottic LSCC 
[42,41]. In T3 and T4 LSCC non-surgical treatment failures range from 68-78.4% 
[43,37]. For these individuals the only remaining curative treatment is salvage partial or 
total laryngectomy.  
 
Overall complication rates from salvage laryngectomy are high (42%), the commonest 
being pharyngocutaneous fistula (28.9%), swallowing difficulties (18.6%), stomal 
stenosis (17.5%), wound infection (14.1%) and bleeding (5.9%) [44]. Strategies to limit 
these complications include the use of local pectoralis major flaps or free tissue flaps 
e.g. anterolateral thigh free flap/ radial forearm free flap. Both free and local tissue 
transfer have an associated risk, cost and morbidity for patients [45]. In addition, overall 
survival is lower for patients treated with salvage laryngectomy after chemo-
radiotherapy compared to radiotherapy alone, the cause for this is unclear but may relate 
to the long-term toxicity of chemotherapy [46].    
 
Alongside patient factors including performance status, the TNM classification is 
widely adopted as the cornerstone for guiding treatment decisions in LSCC. This 
classification system does not predict the likely response of a tumour to radiotherapy. 
With a rising proportion of LSCC patients receiving chemo-radiotherapy and some 
authors associating this with potentially reduced overall survival [47] there is an urgent 
clinical need to determine predictors of radiotherapy failure in LSCC. These would 
allow appropriate patients to undergo primary surgery (TLM or partial/total 
laryngectomy), avoiding the morbidity associated with chemo-radiotherapy and salvage 
laryngectomy and potentially improving overall survival. 
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The epidermal growth factor receptor (EGFR) is overexpressed in more than 80% of 
HNSCCs [48,49] and is associated with poorer prognosis, increased loco-regional 
recurrence and resistance to radiotherapy [14,15]. When given in combination with 
radiotherapy, the anti EGFR monoclonal antibody Cetuximab can improve 5-year 
survival from 36.4% to 45.6% when compared to radiotherapy alone [18]. However 
Cetuximab has failed to overcome radiotherapy resistance in the majority of patients 
[18,1].  
 
There is increasing evidence for cross talk between EGFR and insulin like growth factor 
receptor type 1 (IGF-1R) [50,51]. IGF1R over-expression has previously been linked 
with radiotherapy resistance in other solid organ tumours like breast [52] and cervical 
cancer [53] and levels are known to be elevated in HNSCC [54]. Our group has 
previously reported IGF-1R expression in 92% of HNSCCs. We found that overall and 
disease specific survival was reduced in patients with elevated IGF-1R expression in 
their cancers, and IGF-1R up-regulation was associated with HPV negativity and higher 
tumour T-stage [54]. Other than a single study [55] there is little clinical data available 
to assess the impact of IGF-1R expression in predicting radiotherapy resistance in 
LSCC.   
 
1.2 Aims: 
To assess IGF-1R and EGFR expression in patients treated with radiotherapy for LSCC 
and compare receptor levels in patients receiving radiotherapy without known 





A study was designed to compare total, membranous and cytoplasmic levels of IGF-1R 
and EGFR in patients with LSCC that had and had not responded to primary 
radiotherapy. The study also included measurements of the expression of EGFR and 
IGF-1R in patients undergoing primary and salvage total laryngectomy.   
 
This study was conducted with ethical approval (ref no. 07/H0606/120) from the Health 
Research Authority (NRES committee South Central).  
 
1.3.1 Patient and Tumour Specimens 
All patients who had undergone salvage laryngectomy from January 2004 to January 
2016 at Oxford University Hospitals NHS Foundation Trust were identified from the 
Oxford Head and Neck Cancer Database. There were a total of 25 such cases. Twenty-
five patients treated successfully with primary radiotherapy with no known recurrence 
(RwR) and 25 patients treated with primary total laryngectomy during the same period 
were also selected at random from the database.  
 
Diagnostic samples of formalin fixed, paraffin-embedded LSCC tissues were obtained 
from these cases. From the salvage laryngectomy group additional specimens were 
obtained where available, including biopsies of the recurrent tumour and salvage 
laryngectomy specimen. A consultant head and neck pathologist reviewed tissue blocks 
to confirm the presence of tumour tissue before 4µm whole mount sections were 
prepared.   
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Tumour samples were available from 63 of the 75 patients identified for the study. The 
included patient specimens were categorised into 3 groups for analysis: those 
experiencing radiotherapy without known recurrence (RwR) (n=23; mean follow up 4.1 
yrs, range 1-5yrs), those undergoing primary total laryngectomy (n=22) and those 
treated with initial radiotherapy followed by local or regional recurrence and salvage 
laryngectomy (‘radiotherapy failure’; n=18). The included samples are summarised in 
Figure 1-1.  
 
 
Figure 1-1: A flow diagram to represent included patient samples and available IHC 
results.  
Abbreviations: 1°, primary; TL, Total Laryngectomy; Rtx, Radiotherapy; STL, salvage total 
laryngectomy; SF, sample failure; EGFR, epidermal growth factor receptor; IGF-1R, insulin like growth 
factor receptor type 1, RwR, radiotherapy without known recurrence.   
 
In the radiotherapy failure group there were 7 primary biopsies, 14 biopsies taken at the 
time of recurrence and 11 from salvage laryngectomies. Immunohistochemistry (IHC) 
for IGF-1R was not interpretable in 2 cases of primary laryngectomy and in 1 case of 
salvage laryngectomy whilst IHC for EGFR was not interpretable in 2 cases from the 












































Case note review was performed for each patient to record demographic details, tumour 
stage (TNM staging), ASA (ASA, American Society of Anaesthesiologists Performance 
Status), treatment and clinical outcomes.  
 
1.3.2 Immunohistochemistry 
Immunohistochemistry was performed for EGFR and IGF-1R as previously described 
[54,56,57]. Freshly cut 4 µm whole mount sections were de waxed in Citroclear (TCS 
Biosciences Ltd, UK) twice for 8 minutes before being serially rehydrated in decreasing 
concentrations of ethanol (100%, 80%, 70% and 50%) for 2 minutes each followed by 
distilled water for 5 minutes. Antigen retrieval was performed in Tris/EDTA buffer  
(Trisma base 50nM, EDTA 2nM, pH 9) for IGF-1R and Citrate buffer (10nM citric 
acid, 0.05% Tween 20, pH 6) for EGFR in a decloaking chamber (DC2002, Biocare 
Medical) at 125°C and 85°C for 8 and 10 minutes respectively. Slides were washed in 
phosphate buffered saline (PBS) before blockade of endogenous peroxidase using 3% 
hydrogen peroxide for 10 minutes. Sections were subsequently blocked with 5% bovine 
serum albumin (BSA)/5% goat serum (GS) in PBS for 60 minutes. Primary EGFR 
antibody (no.4267, Cell Signalling Technology) and primary IGF-1R antibody 
(no.9750, Cell Signalling Technology) were applied respectively at 1:200 and 1:50 
dilution in 5% BSA/5%GS in PBS overnight at 4°C. After 3 serial washes in PBS (5 
minutes each), secondary antibody (Rabbit HRP-polymer, Menarini Diagnostics) was 
applied for 30 minutes followed by diaminobenzidene substrate (Envision) for 5 
minutes at room temperature. Sections were counter-stained using Mayer’s 
haematoxylin (Vector Laboratories) for 20 seconds and serially dehydrated in 
increasing concentrations of alcohol (50%, 70%, 80% and 100%) and Citroclear for 5 
minutes each. The sections were mounted using DePex reagent (VWR International, 
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UK). Each staining run included control slides of sections taken from cell pellets of 
SKUT-1 (known to be deficient in IGF-1R and abundant in EGFR) and MCF7 (known 
to have relatively weaker EGFR expression and abundant IGF-1R expression)[57,58]. 
 
Whole mount sections were scored for membrane and cytoplasmic EGFR and IGF-1R 
within tumour cells only by two observers (AQ and KS). The scorers were blinded to 
the treatments patients had received. Any differences in score were resolved by 
consensus decision using a microscope with an additional teaching arm. A previously 
described method was used [59] to provide scores for intensity (0, no staining; 1, weak; 
2, moderate; 3, heavy) and percentage of tumour involved (0%, nil; 1: 1–10% of tumour 
stained; 2: 11–50%; 3: 51–80%; 4: 81–100%). The two scores were multiplied to give 
an immunoreactive score (IRS, range 0-12) for the membrane and cytoplasm and then 
combined to give the total IGF-1R or EGFR score (range: 0-24). Figure 1-2a and 1-2b 
are examples of cytoplasmic and membranous staining and the scores given for EGFR 










Figure 1-2a: Intensity scores of EGFR staining in LSCC whole mount sections.  
Examples of EGFR staining of tumour membrane and cytoplasm using IHC to illustrate patterns of 
intensity used to determine immunoreactivity scores. All tumour samples had ‘heavy’ levels of membrane 





























Figure 1-2b: Intensity scores of IGF-1R staining in LSCC whole mount sections.  
Examples of IGF-1R staining of tumour membrane and cytoplasm using IHC to illustrate patterns of 






























1.3.3 Statistical Analysis 
All statistical analyses were pre-determined and performed using Prism 7 for Mac OS X 
(© 1994-2015 GraphPad Software, Inc). The demographic differences in the patient 
population based on primary treatment and treatment response were assessed with a 
two-tailed Chi-squared test.  Median IRS scores determined by IHC were compared 
using a two-tailed Mann-Whitney U test when comparing two unpaired groups and a 
pairwise Mann-Whitney U test when comparing 3 or more. Association was assessed 
using Pearson’s correlation and least squares linear regression. A result was considered 
significant when p was <0.05.  
 
1.4 Results: 
The mean age of study subjects was 66 years (range: 37- 87yrs) (see Table 1-1).  There 
were 56 males (88.9%) and 7 females (11.1%). Average alcohol consumption was 18.2 
units/week; there were 50 (79.4%) current or ex-smokers with an average 33.6 pack 
year (range: 10-120) smoking history. The majority of patients treated initially with 
radiotherapy presented with T1/2 disease (75.6%) whilst those treated with primary 
total laryngectomy had T3/4 disease (100%). There were 23 patients in the radiotherapy 
without known recurrence (RwR), 18 in the radiotherapy failure and 22 in the primary 
total laryngectomy groups respectively. In the radiotherapy failure group the average 









Table 1-1: Patient Demographics and Tumour Characteristics by Primary Treatment.  
Comparisons are made using Chi2 analysis. Patients with RwR and Rtx failure had similar sized tumours 
and patient characteristics. As expected, patients treated with primary laryngectomy had advanced stage 
tumours.  
 
Abbreviations: ASA, American Society of Anaesthesiologists Performance Status; n/a, not applicable; 
Tx, treatment; Gy, Gray; Fr, fractions; RwR, radiotherapy without known recurrence.  
 













Sex     
Male 23(100) 16(88.9) 17(77.3) 0.053 
Female 0(0) 2(11.1) 5(22.7)  
Age    
>65 15(65.2) 9(50) 12(54.5) 0.59 
<65 8(34.8) 9(50) 10(45.5)  
ASA     
1/2 21(91.3) 15(83.3) 22(100) 0.15 
3/4 2(8.7) 3(16.7) 0(0)  
Smoking Status    
 Never 8(34.8) 3(16.7) 2(9.1) 0.26 
Current 9(39.1) 8(44.4) 13(59.1)  
Ex-smoker 6(26.1) 7(38.9) 7(31.8)  
Drinking Status    
Nil 12(52.2) 13(72.2) 10(45.5) 0.53 
1-21 units/week 5(21.7) 1(5.6) 4(18.2)  
22-40 units/week 4(17.4) 2(11.1) 3(13.6)  
>40 units/week 2(8.7) 2(11.1) 5(22.7)  
T Classification    
T1/2 17(73.9) 14(77.8) 0(0) 0.001 
T3/4 6(26.1) 4(22.2) 22(100)  
N Classification    
N0/1 22(95.7) 17(94.4) 14(63.6) 0.005 
N2/3 1(4.3) 1(5.6) 8(36.4)  
M Classification    
M0 23(100) 18(100) 22(100) n/a 
M1 0(0) 0(0) 0(0)  
Radiotherapy Tx     
55Gy 20Fr 19(82.6) 12(66.7) n/a  
60-66Gy 30-33Fr 4(17.4) 2(11.1) n/a 0.80 
Unknown 0(0) 4(22.2) n/a  
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There were no statistically significant differences between the 3 groups in terms of age, 
sex, co-morbidity, alcohol consumption, smoking status and radiotherapy treatment 
regimen, although there were proportionately fewer smokers in the RwR group. Patients 
treated with primary total laryngectomy presented with a higher T stage and N-
classification than those treated successfully and unsuccessfully with radiotherapy 
(p<0.01). There were no patients with distant metastases.    
 
1.4.1 Radiotherapy without known Recurrance vs. Radiotherapy Failure 
Primary biopsies from patients with RwR (n=23) were compared to primary biopsies 

































































































































































































































































































































































































































































































































The membrane, cytoplasmic and total IGF-1R scores were higher in the radiotherapy 
failure group (2.29, 3.14, 5.43 vs. 1.00, 2.17, 3.17 respectively) although the differences 
were not statistically significant (membrane IGF-1R p=0.2, cytoplasmic IGF-1R 
p=0.54, total IGF-1R p=0.40; Figure 1-3a).  
 
Primary biopsies from those receiving RwR (n=23) were then compared to biopsies 
taken following disease recurrence (n=14) (see Figure 1-1). The membrane, 
cytoplasmic and total IGF-1R scores were higher in the radiotherapy failure group 
(respectively 3.07, 3.36, 6.43 vs. 1.0, 2.17, 3.17 p=0.004, p=0.18, p=0.01). The 
difference in membrane and total IGF-1R were statistically significant (Figure 1-3b).   
 
An additional analysis was conducted comparing the mean IGF-1R IRS scores of all 
available specimens from patients with radiotherapy failure (n=18) to those receiving 
RwR (n=23) (Figure 1-3c). Membrane, cytoplasmic and total IGF-1R scores were 
higher in the radiotherapy failure group (3.04, 3.62, 6.66 vs. 1.0, 2.17, 3.17, p=0.009, 
p=0.08, p=0.01). The results were significant when comparing membrane and total IGF-








































































































































































































Similar comparisons were made between membrane, cytoplasmic and total EGFR 
scores between patients with RwR and radiotherapy failure (see Table 1-3 and Figure 
1.4). There was no statistically significant difference in EGFR expression between the 























































































































































































































































































































































































































































































































































































































































1.4.2 Radiotherapy Failure: Primary vs. Recurrence  
Pre and post radiotherapy membrane, cytoplasmic and total IGF-1R and EGFR scores 
were compared in the radiotherapy failure group to determine whether IGF-1R 
expression had altered after radiotherapy.  
 
There were 6 patients with radiotherapy failure, from whom both pre and post 
radiotherapy tumour samples were available. A paired t-test analysis was conducted to 
assess IGF-1R and EGFR levels pre and post radiotherapy in these individuals (Table 
1-4a, Table 1-4b, Figure 1-5a and Figure 1-5b). Membrane, cytoplasmic and total 
IGF-1R scores all showed a significant increase after radiotherapy (2, 2.3, 4.3 vs. 4.2, 
4.3, 8.5 p<0.05). Whilst membrane, cytoplasmic and total EGFR levels did rise after 
radiotherapy (9, 2.67, 11.67 vs. 11, 3.83, 14.83 p>0.05), the increases were not 

































































































































































































































































































































































































































































































































































































































Figure 1-5a: IRS for IGF-1R in Primary vs. Recurrent Biopsies in Paired Specimens 
from the Same Patient. Graphs show paired membrane, cytoplasmic and total IGF-1R 
scores pre and post radiotherapy in patients with Rtx failure. The connecting line 
represents paired samples.  
 
Abbreviations: Rtx, radiotherapy; IRS, immunoreactive score. 
 
 
Figure 1-5b: IRS for EGFR in Primary vs. Recurrent Biopsies in paired specimens 
from the same patient. Graphs show paired membrane, cytoplasmic and total EGFR 
scores pre and post radiotherapy in patients with Rtx failure. The connecting line 
represents paired samples.  
 

















































































1.4.3 Primary vs. Salvage Total Laryngectomy 
The membrane, cytoplasmic and total IGF-1R and EGFR levels were also compared 
between primary total laryngectomy and salvage laryngectomy to see if previous 
radiotherapy or advanced disease were associated with IGF-1R and EGFR expression 
(see Table 1-5 and Figure 1-6). There was no significant difference between the two 
groups in terms of membrane, cytoplasmic and total IGF-1R (p=0.62, p=0.78, p=0.87) 






















































































































































































































































































































































































































































































































































































































































































































1.4.4 Radiotherapy without known Recurrence vs. Primary Total Laryngectomy 
Tumour samples from patients with RwR were compared to samples taken from 
primary total laryngectomies (see Table 1-2, 1-3 and Figure 1-7). As expected patients 
undergoing primary total laryngectomy had a higher T and N stage (p<0.05). The 
membrane, cytoplasmic and total IGF-1R levels were significantly higher in the primary 
total laryngectomy group (4.25, 4.05, 8.30 vs. 1.00, 2.17, 3.17, p=0.0003, p=0.02, 
p=0.02) whilst there was no difference in EGFR scores (10.55, 5.77, 16.32 vs. 10.33, 















































































































































































































1.4.5 IGF-1R Levels and Time to Recurrence 
Membrane, cytoplasmic and total IGF-1R and EGFR scores were compared to the time 
taken for recurrence in the radiotherapy failure group to see if IGF-1R and EGFR levels 
were associated with earlier disease recurrence (see Figure 1-8). There was no 
correlation between IGF-1R or EGFR levels and time to disease recurrence. 
 
 
Figure 1-8: Total IGF-1R and EGFR vs. time to recurrence in Rtx failure group.  
Graphs show correlation between IGF-1R and EGFR total scores and time to 
recurrence in patients with Rtx failure.  
 
Abbreviations: Rtx, radiotherapy; r, Pearson’s correlation coefficient; EGFR, epidermal growth factor 
























































1.4.6 Correlation Between IGF-1R and EGFR 
Where both EGFR and IGF-1R expression was detected in the same sample, IRS scores 
were compared. There was no statistically significant correlation between membrane, 
cytoplasmic and total EGFR and IGF-1R in patients with RwR, radiotherapy failure or 
primary total laryngectomy alone. When the results for all samples were combined (see 
Figure 1-9), higher levels of EGFR were associated with elevated IGF-1R levels          
(r = 0.26 ;0.03-0.45 95% confidence interval, p=0.02).  
 
Figure 1-9: Correlation between Total IGF1R and Total EGFR in all samples where 
IGF-1R and EGFR IHC was performed.  
The line of best fit is displayed and demonstrates a correlation between IGF-1R and 
EGFR levels.  
 
Abbreviations: r, Pearson’s correlation coefficient; EGFR, epidermal growth factor receptor; IGF-1R, 


























Radiotherapy failure in the context of LSCC can have disastrous consequences on 
patients both in terms of radiotherapy related morbidity and complications of salvage 
surgery.  Given the rising proportion of patients receiving primary radiotherapy for 
LSCC and static overall survival [27] there is a clinical need to identify biomarkers of 
radiotherapy resistance in this group of patients. This study was designed to determine 
if levels of IGF-1R expression were able to predict radiotherapy resistance in 
individuals with LSCC.  
 
This study compared patients experiencing RwR vs. recurrence following radiotherapy 
for LSCC. The groups were similar both in terms of tumour size and patient factors. 
IGF-1R IHC in the primary biopsies showed a trend to higher pre-treatment IGF-1R 
levels in patients experiencing radiotherapy failure, although the differences were not 
statistically significant. This may have been due to relatively low sample numbers (n=7) 
in the radiotherapy failure group. EGFR levels were similar when comparing patients 
experiencing RwR vs. radiotherapy failure.  
 
This conflicts with previously published evidence that higher levels of EGFR associate 
with radiotherapy resistance in HNSCC [60,61]. Demiral et al (2004) [61] found higher 
levels of EGFR associated with radiotherapy resistance in early glottic cancer. In the 
present larger study, all tumour specimens were found to express high levels of 
membrane EGFR, this may have reflected the cohort of patients selected, IHC or 
scoring method utilised.   
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To determine if IGF-1R expression was elevated post radiotherapy we compared IGF-
1R levels from patients with radiotherapy failure prior to and following radiotherapy. A 
paired analysis of tumour samples taken pre and post radiotherapy demonstrated a 
significant increase in membrane, cytoplasmic and total IGF-1R post irradiation. These 
results suggested a potential association between elevated IGF-1R and radiotherapy 
resistance and rising IGF-1R levels following radiotherapy in LSCC.  
 
The IGF-1R is a receptor tyrosine kinase known to have a role in cell cycle progression, 
proliferation, differentiation, survival, malignant transformation, tumour invasion, 
metastasis and inhibition of cellular apoptosis [62]. Radiotherapy induces DNA damage 
through nucleotide excision, single and double stranded breaks, the latter being the most 
significant for cellular death [63]. In some cases cells are able to repair DNA damage; if 
this does not take place the process of apoptosis begins [63]. There are two primary 
mechanisms for cellular repair; homologous recombination (HR) and non homologous 
end joining (NHEJ) [64]. NHEJ is present throughout the cell cycle and is the most 
extensive repair pathway for double stranded break DNA repair in mammals [65]. 
During NHEJ, damaged bases are resected and the ends re-joined resulting in a loss of 
information within damaged cells. This process introduces genomic instability and may 
favour survival amongst altered phenotypes. IGF-1R overexpression is thought to help 
mediate this mechanism, thereby favouring malignant transformation alongside 
resistance to radiotherapy [63,66], it might also be up regulated after irradiation as seen 
in the present study.  
 
Following radiotherapy non-cancer cells typically undergo apoptosis, however cancer 
cells particularly those resistant to radiotherapy can behave very differently, and up 
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regulation of IGF-1R after radiotherapy could be the result of an altered response to 
irradiation and DNA repair. Dysregulation of the ‘normal’ cell cycle and resistance to 
programmed cell death are some of the hallmarks of cancer [67]. Radiotherapy induces 
DNA damage, which if left unrepaired typically results in programmed cell death. 
Malignant cells however, are often resistant to the normal molecular mechanisms for 
cell cycle regulation, programmed cell death and DNA repair e.g. p53 mutation and 
NHEJ [68]. They exhibit increased cellular proliferation, altered DNA repair and 
resistance to apoptosis, IGF-1R is involved in each of these cellular processes [63].  
 
IGF-1R signalling along the MAPK pathway results in increased cellular proliferation 
[69]. IGF-1R also associates with the function of ATM kinase (a protein critical for cell 
cycle progression by regulating cell proliferation and inhibiting apoptosis along the 
PI3K pathway) [70]. ATM kinase is usually activated in response to ionising radiation 
resulting in DNA repair, apoptosis and cell cycle arrest, however up regulation of IGF-
1R is known to inhibit this effect and can result in altered DNA repair [71]. The present 
study demonstrated up regulation of IGF-1R after radiotherapy in patients with 
radiotherapy failure, this could be a feature of tumours with an innate resistance to 
radiotherapy due to elevated IGF-R. It might also reflect the selective survival of 
tumour cells within heterogenous tumours exhibiting higher IGF-1R levels.  It might 
also be a direct consequence of altered DNA repair after radiotherapy promoting the 
survival of cells expressing elevated IGF-1R given the survival advantage it provides 
malignant cells. The true mechanism is likely to be multifactorial and requires further 
characterisation and investigation.  
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There are multiple studies over the past 2 decades evaluating the prognostic value and 
relative radiotherapy resistance due to IGF-1R overexpression in other solid organ 
tumours. In vitro, studies suggest that IGF-1R expressing mouse embryo fibroblasts, 
murine melanoma cells and human breast cancer cells can be radio-sensitised by 
targeting IGF-1R [72-74]. Our study design and results were similar to the first clinical 
study looking at IGF-1R as a potential marker of radiotherapy resistance. Turner et al 
(1997) [73] compared tumour tissue taken from breast cancer patients following early 
local relapse after radiotherapy to those without relapse and found significantly higher 
IGF-1R levels in the radiotherapy failure group. Following their work there have been 
similar studies demonstrating elevated levels of IGF-1R in radiotherapy resistant 
cervical cancer [53,75] and an association between IGF-1R overexpression and survival 
in colorectal [76] and non-small cell lung cancer [77]. A single study has contradicted 
these finding; Peiro et al (2009) [78] reported better treatment response for patients with 
high levels of IGF-1R treated with lumpectomy and radiotherapy for breast cancer. 
Differences between the IHC and scoring methods used by these authors and in the 
literature and a lack of data relating to patient selection has made interpretation of these 
results in the context of other studies difficult.  
 
The relationship between IGF-1R expression and HNSCC has previously been 
investigated. Studies of nasopharyngeal [79] and oral cavity cancers [80] have shown 
poorer outcomes from radiotherapy for patients with higher levels of IGF-1R. Previous 
work from our group has also highlighted an association between high levels of IGF-1R 
and T-stage, HPV negative status and adverse survival in HNSCC [54]. The results of 
the present study support these findings, as we found higher levels of IGF-1R in 
samples taken from primary and salvage laryngectomies when compared to patients 
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receiving primary radiotherapy, suggesting a positive association between IGF-1R 
expression and larger tumour or T-stage.  
 
Given these results, IGF-1R levels might represent a surrogate marker of T-stage. 
Studies have previously shown an association between IGF-1, IGF-1R levels and 
tumour growth, depth of invasion and lymphatic and venous invasion in colorectal, lung 
and head and neck cancer [81,82,54]. As IGF-1 is one of the growth factors associated 
with normal cellular growth [83], and deletion of IGF-1R causes a 50% reduction in the 
size of mouse embryos [84] and drosophila [85] this might explain the correlation 
between IGF-1R expression and increased tumour size. The increase in tumour size 
associated with IGF-1R levels might also explain the association of elevated IGF-1R 
with decreased overall survival for a number of solid organ tumours including head and 
neck cancer and lung cancer [86,54].  
 
Matsumoto et al (2016) [55] assessed IGF-1R levels using IHC in patients with early 
stage LSCC treated with primary radiotherapy. In their study of diagnostic biopsies 
from 43 patients, local recurrence was experienced by 9 of 25 patients with high IGF-
1R and 1 of 18 of those with low tumour IGF-1R. They found no association between 
IGF-1R levels and time to recurrence, as did our study.  
 
However, the association of high IGF-1R with an increased likelihood of radiotherapy 
failure, was not absolute, as Matsumoto et al (2016) [55] reported treatment failure in 
one patient with low IGF-1R and successful treatment in 16 patients with high IGF-1R 
levels. Despite their findings, they concluded primary radiotherapy be utilised as first 
line treatment for early glottic cancer irrespective of any predictive factors.  
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These conclusions are based on the presumption that salvage surgery remains a viable 
curative option for patients with radiotherapy failure, and that radiotherapy provides 
superior functional outcomes in comparison to primary surgery. Whilst these 
conclusions are logical, there is sufficient evidence to suggest at least equivalent 
functional outcomes for patients treated with radiotherapy and surgery in laryngeal 
cancer. With regards to voice, Taylor et al (2013) [87] reported equivalent functional 
outcomes for patients with early laryngeal cancer treated with primary trans oral 
microsurgery and radiotherapy.  In fact, a recent meta-analysis found superior voice 
outcomes for patients treated with laser surgery when compared to radiotherapy [88]. 
Burnip et al (2013) [89] reported similar swallowing outcomes for patients undergoing 
radiotherapy or surgery in advanced laryngeal cancer. Whilst the retrospective nature of 
these studies is a limiting factor their conclusions should not be ignored. An alternative 
conclusion that Matsumoto et al (2016) [55] may have considered, would have been to 
recommend the most effective primary treatment based on tumour predictors. This 
might be radiotherapy or surgery with salvage surgery or radiotherapy held in reserve in 
the case of treatment failure. This approach might limit patient morbidity by utilising 
single modality treatment and potentially improve overall survival.   
 
The present study included a larger number of patients with both early and advanced 
stage tumours and assessed EGFR in addition to IGF-1R when compared to Matsumoto 
et al (2016) [55]. Given the recent description of EGFR as one of the hallmarks of head 
and neck cancer [90] and the potential for cross communication with IGF-1R via the 
P13K/AKT pathway [91] we felt it was important to evaluate both receptors 
simultaneously. Interestingly, our study found a weakly positive association between 
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EGFR and IGF-1R expression, further adding to the evidence behind a biological 
association between these two receptor tyrosine kinases [51,92,91]. 
 
Our IHC score for IGF-1R included assessment of both intensity and proportion of 
tumour stained to determine an IRS, whilst Matsumoto et al [55] assessed only 
proportion of tumour stained to determine IGF-1R expression. Using this single stage 
method relatively low intensity widespread staining could be interpreted as high 
expression whilst this would not occur with the two-stage method used in our study. It 
is possible, therefore, that Matsumoto et al [55] may have overestimated the proportion 
of patients with high IGF-1R and conversely underestimated the prognostic value of 
IGF-1R in detecting radiotherapy failure.  
 
Other strengths of our study included the use of blinding to limit bias during IHC 
interpretation, the use of adjacent tumour sections when comparing EGFR and IGF-1R 
and control samples for each IHC staining run. Our study was limited by its 
retrospective nature, low numbers of diagnostic samples in the radiotherapy failure 
group, missing samples and the generic limitations of IHC interpretation. Whilst two 
scorers were used to overcome subjectivity and conflicts were resolved by consensus 
interpretation using a microscope with a teaching arm, the nature of IHC meant that 
only a representative portion of the tumour was analysed. Although whole mount 
sections are superior to tissue microarrays in large or particularly heterogeneous 
tumours they may not represent the true tumour profile. A variation in the total length of 
follow up for patients with RwR (range 1-5yrs) might also have influenced the 
outcomes of comparisons.  
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The present study suggests that IGF-1R is up regulated following radiotherapy for 
LSCC, and provides support from previous investigations into IGF-1R [54,60,79,80] for 
an association between elevated IGF-1R and radiotherapy resistance in LSCC and other 
types of HNSCC.  
 
So far only human papilloma virus (HPV) has shown promise as a biomarker for 
treatment decisions in oropharyngeal squamous cell carcinoma (OPSCC) [93]. There 
are no clinically utilised biomarkers for personalised therapy in LSCC. If our results are 
replicated in large-scale prospective studies, IGF-1R status could help refine current 
treatment decisions. Much like HPV testing for OPSCC, IGF-1R testing could 
contribute to treatment decisions in LSCC. Patients with high IGF-1R could be offered 
primary surgery with radiotherapy and chemotherapy held in reserve. This could alter 
current trends towards primary radiotherapy based on TNM status and patient factors 
[30] to treatment guided by the molecular profile or IGF-1R status of tumours. Before 
implementing these changes it will be necessary to determine the clinically relevant 
definition of ‘IGF-1R overexpression’ given the lack of a current consensus regarding 
this.  
 
Personalised medicine has become a reality in the management of many solid organ 
tumours including breast, ovarian, prostate, colorectal, skin and non-small cell lung 
cancer[4]. Treatments for HNSCC however have not kept pace; testing for IGF-1R 
status or molecular therapies aimed at targeting this receptor [94,95] may help to 





This study found a trend to higher IGF-1R in primary biopsies of patients with LSCC 
experiencing radiotherapy failure, with evidence of significant IGF-1R up regulation 
following radiotherapy. IGF-1R levels were also positively associated with increased 
tumour size and weakly associated with EGFR expression. This could mean that IGF-
1R expression might also represent a surrogate measure of T stage. There was also a 
weak association between radiotherapy and up regulation of EGFR, although this was 
not statistically significant.   
 
Whilst these results should be interpreted cautiously given the retrospective design, 
missing data and relatively small numbers, it is the largest study of its type and the 
results warrant further investigation.  The outcomes from on-going trials of IGF-1R 
inhibition using monoclonal antibodies independently and in combination with EGFR 
monoclonal antibody Cetuximab [96-98] may provide further prognostic information 
for the role of IGF-1R in radiotherapy resistant HNSCC. Prospective large-scale multi-
centre trials are needed to test these findings and determine the ‘clinically relevant’ 










Chapter 2: Investigating Insulin-Like Growth Factor Receptor 1 (IGF-1R) as a 




There is a clinical need for predictive biomarkers of radiotherapy resistance in laryngeal 
cancer (LSCC). At present we are unable to predict the individuals likely to benefit 
from radiotherapy and which are likely to fail. The drivers of radiotherapy resistance in 
LSCC are unclear, but both the epidermal growth factor receptor (EGFR) and insulin 
like growth factor receptor type 1 (IGF-1R) have been implicated. 
 
Aims: 
To develop an in vitro model of radiation resistance in laryngeal cancer cells, 
characterise EGFR and IGF-1R expression and activation, and investigate the effects of 
EGFR and IGF-1R inhibition on radio-sensitivity.   
 
Methods: 
Two laryngeal cancer cell lines (BICR18 and SQ20B) were repeatedly irradiated using 
clinically utilised radiotherapy treatment schedules to a total of 55 or 60 Gray (Gy). 
Western blots were used to compare IGF-1R, EGFR and downstream target expression 
and activation between the parental and irradiated cell lines. Clonogenic survival assays 
(CSAs) were used to assess relative radiotherapy resistance. Cells were treated with 
BI836845 (IGF ligand antibody) and Afatinib (EGFR receptor tyrosine kinase inhibitor) 
alone and in combination to determine the effects on response to radiation. Drug 
efficacy and radiation response was tested using western blots and CSA. 
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Results: 
SQ20B cells expressed IGF-1R and EGFR, BICR18 cells expressed IGF-1R with no 
detectable EGFR. In SQ20B cells there was evidence of receptor cross talk, whereby 
EGF ligand was shown to activate IGF-1R. SQ20B cells irradiated to a dose of 55Gy 
were more radio-resistant than parental cells. Repeated irradiation of BICR18 cells did 
not produce a radiotherapy resistant phenotype. Both irradiated cell lines demonstrated 
increased IGF-1R expression and EGFR was increased in irradiated SQ20B cells. 
EGFR inhibition was found to radio sensitize SQ20B cells, but combined EGFR/IGF-
1R inhibition was no more effective. However, assays of basal cell survival (in absence 
of radiotherapy) in SQ20B cells showed that combined EGFR/IGF-1R inhibition was 
more effective, than either single agent, this effect was greater in previously irradiated 
cells.   
 
Conclusions: 
IGF-1R was up regulated following repeated irradiation in LSCC cell lines, but did not 
appear to be a driver of radiotherapy resistance. Combined IGF-1R and EGFR 
inhibition reduced cell survival in the absence of radiation in repeatedly irradiated 
SQ20B cells, suggesting induced dependence on these pathways. Further work is 
needed to understand the interaction between EGFR and IGF-1R in radiotherapy 







2.1 Background:  
T1-T2 laryngeal squamous cell carcinoma (LSCC) is frequently treated with 
radiotherapy[34]. Some centres have reported 5-year survival at 94% [99] whilst others 
have reported local or regional recurrence in up to 21% and 37% of T1 and T2 glottic 
LSCCs respectively [40,41]. The mechanisms for radiotherapy resistance in LSCC are 
unclear, but both the epidermal growth factor receptor (EGFR) [90] and insulin like 
growth factor receptor 1 (IGF-1R) have been implicated[54].  
 
Clarification of the role for these two receptor tyrosine kinases (RTKs) and their 
interaction could aid prediction of radiotherapy resistance in LSCC. The presence and 
abundance of both IGF-1R and EGFR may represent important biomarkers for 
predicting treatment response in LSCC.   
 
EGFR and IGF-1R in Laryngeal Cancer 
EGFR is a receptor tyrosine kinase (RTK) present in the plasma membrane and cell 
nucleus and is a promising therapeutic target in head and neck cancer (HNSCC) [13]. 
EGFR overexpression is considered one of the ‘hallmarks of HNSCC’ [90]. It is 
overexpressed in more than 80% of HNSCCs [48,49] and is present in the early stages 
of tumor genesis, marking it as a potential driver of tumour formation. EGFR levels are 
typically 1.7x greater in HNSCC tissue than in the squamous epithelium of non-smokers 
without HNSCC [100]. EGFR overexpression is also seen in the normal epithelium of 
HNSCC patients, and may contribute to the 36% risk of a second primary tumour [101]. 
As mucosa transitions from premalignant to malignant disease, EGFR expression is 
known to increase, and is associated with a poorer prognosis, increased loco-regional 
recurrence and increased resistance to radiotherapy [14,15].  
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In vitro, Cetuximab a monoclonal antibody to EGFR causes HNSCC cells to 
accumulate in the G1 phase of the cell cycle, inhibiting proliferation and increasing 
radiotherapy sensitivity [102]. Randomized controlled trials (RCT) of radiotherapy vs. 
radiotherapy and Cetuximab in HNSCC have shown loco-regional control and 5-year 
survival of 14.9 months and 36.4% vs. 24.4 months and 45.6% respectively [17,18]. On 
this basis, Cetuximab is now licensed for use in patients unsuitable for treatment with 
Cisplatin. However, we are still no closer to knowing which patients are most likely to 
benefit from this treatment [103].  
 
An important issue with Cetuximab and other agents targeting EGFR is the 
development of treatment resistance [104]. The mechanisms for this remain unclear; 
receptor cross talk may have a role. EGFR and IGF-1R both communicate through the 
P13K/AKT [91] and RAS [105,106] signalling pathways. AKT and ERK are communal 
downstream targets for both receptors. The PI3K/AKT pathway has been implicated in 
cell growth and contributes to protein synthesis, cell proliferation and protection from 
apoptosis [92,91]. The tumour suppressor PTEN is known to regulate this pathway, loss 
of its activity can result in hyperactive signalling along this pathway [107]. The RAS 
pathway contributes towards regulation of the cell cycle and cellular proliferation (see 







Figure 2-1a: Signalling pathway for IGF-1R and EGFR [92,91] 
Abbreviations: IGF, insulin growth factor; IGF-1R, insulin like growth factor receptor type 1; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; GPCR, G-protein coupled receptor.  
 
This figure demonstrates the activation of IGF-1R and EGFR by their respective ligand molecules and 
subsequent downstream signalling.  Both receptors are known to communicate via the PI3K and RAS 
signalling pathways. These pathways are involved in cellular growth and proliferation respectively. 
Drugs targeting one of these receptors may prove ineffective, as compensatory downstream signalling 




























The P13K/AKT and RAS signalling cascades are frequently mutated in cancer 
[108,109]; treatments targeting these pathways can result in anti-proliferative, anti-
invasive and anti-angiogenic effects in HNSCC. It is plausible that dual inhibition of 
IGF-1R, EGFR and their downstream effectors could overcome resistance and improve 
treatment efficacy [51]. 
 
Receptor crosstalk is an important area of interest, and can occur when inhibition of one 
RTK e.g. EGFR may be overcome by activation of another e.g. IGF-1R [19,110]. This 
could happen through communal downstream signalling proteins or interaction at the 
cellular surface, several mechanisms have been proposed. These include the formation 
of IGF-1R/EGFR trans membrane complexes or through co-stimulation via 










Figure 2-1b: Proposed mechanism for ‘cross-talk’ between IGF-1R and EGFR (figure 
derived from van de Veeken et al 2009 [51]) 
 
Abbreviations: IGF, insulin growth factor; IGF-1R, insulin like growth factor receptor type 1; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; GPCR, G-protein coupled receptor.  
 
 (A) This figure illustrates a single IGF-1R molecule, with its extracellular α and trans membrane β 
component forming a complex with a single EGFR molecule. It is proposed that both IGF and EGF 
ligand have the potential to stimulate downstream signalling of both receptors. (B) This figure illustrates 
another potential mechanism for ‘cross-talk’ between IGF-1R and EGFR. Here, it is thought that IGF 
ligand results in a stimulus to trans membrane G-protein coupled receptors resulting in the release of 
extracellular EGF ligand, thereby resulting in activation and downstream signalling for the EGFR 




















In previous work from our group, Dale et al [54] studied the expression of IGF-1R in 
HNSCC. They found that IGF-1R was overexpressed in HNSCCs, and high levels of 
IGF-1R associated with HPV negative HNSCC, increased tumour T stage and adverse 
survival. Other components of the insulin growth factor (IGF) axis are also implicated 
in the pathogenesis of HNSCC. High levels of IGFBP-3 are associated with shorter time 
to progression [13], whilst high levels of serum IGF-1 are associated with increased risk 
of second primary tumours [111].  
 
Further investigation is needed to determine the relationship between IGF-1R and 
EGFR pathways in radiotherapy resistant LSCC.   
 
2.2 Aims:  
1. To develop an in vitro model of radiation resistance in laryngeal cancer cells. 
2.  Determine the relative expression and activation of EGFR, IGF-1R and communal 
downstream targets.   
3. To investigate the effects of EGFR and IGF-1R inhibition independently and in 
combination on cell survival and radio resistance in parental and repeatedly irradiated 
cells.   
 
2.3 Methods: 
2.3.1 Cell Culture 
The laryngeal cancer cell lines SQ20B and BICR18 were obtained from Dr Geoff 
Higgins, Dept of Oncology, University of Oxford and European Collection of Cell 
Cultures (ECACC) respectively. Mycoplasma testing was negative (MycoAlert, Lonza 
Rockland Inc, Rockland, United States). Both cell lines were tested by short tandem 
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repeat (STR) genotyping. Short tandem repeats are multiple copies of a short identical 
DNA sequence found in direct succession on particular regions of a chromosome. STR 
allows for cell line specific DNA profiling by looking for a known ‘DNA fingerprint’, 
this is compared to cell specific data held in a public database to confirm the identify of 
cells[112]. STR confirmed the identify of BICR18 however validation was not possible 
for SQ20B due to a lack of public records.  
 
The cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% foetal calf serum (Gibco) and 1% penicillin/streptomycin (Gibco). The 
medium for BICR18 also contained 2mM Glutamine (Gibco) and 0.4 micrograms/ml 
hydrocortisone (Sigma-Aldrich) and for SQ20B 1% non-essential amino acids (Gibco). 
Both cell lines were maintained in a humidified incubator at 37°C, 5% CO2. All cell 
culture was performed in a laminar flow cabinet.     
 
2.3.2 Exposure to Ionising Radiation 
SQ20B and BICR18 cells were plated at a density of 1x106 in T75 flasks and allowed to 
reach 80-90% confluence. Cells were treated using two clinically utilised radiotherapy 
regimes for laryngeal cancer; 55 Gray (Gy) in 20 fractions (Fr) and 60 Gy in 30 Fr. 
Irradiation was carried out using a Caesium-137 irradiator (GSR D1, gamma Service) 
giving a dose of 2.75Gy or 2Gy daily to the cells over 4 and 6 weeks with a two-day 
gap at the weekend to allow recovery. Cells were passaged weekly at 90% confluence. 
Cell lines were allowed 14 days recovery after completing treatment, prior to further 
characterisation.    
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Early and late passages of both parental cell lines were maintained as controls. This 
meant that for each cell line there were 4 subtypes available for analysis. These were 
early passage parental cells (used as a control), late passage parental cells (mirroring the 
number of passages irradiated cells had undertaken), cells treated with 55Gy in 20Fr 
and 60Gy in 30Fr. There were a total of eight cell lines produced, named according to 
the treatment received, early passage BICR18, BICR18, 55GyBICR18, 60GyBICR18, 
early passage SQ20B, SQ20B, 55GySQ20B and 60GySQ20B.  
 
2.3.3 Clonogenic Survival Assays (CSA)  
 
Comparing Relative Radiotherapy Resistance: 
For each cell line 2000 cells (unless otherwise specified) were counted using an 
automated cell counter (Invitrogen Countess, Thermo Fisher Scientific, Loughborough, 
UK) and seeded into triplicate 100mm cell culture dishes and allowed to attach 
overnight. Each dish was irradiated with 0 to 10 Gy, after 7 days the medium was 
removed, cells washed with phosphate buffered saline (PBS) and colonies fixed and 
stained with 50% methanol, 7% acetic acid and 0.1% Coomassie Blue.   
 
Effects of Drug Inhibition: 
To assess the effects of EGFR and IGF-1R inhibition on parental and irradiated 
laryngeal cancer cells, Afatinib (EGFR RTK inhibitor) and BI836845 (IGF ligand 
antibody) were obtained from Selleckchem (Munich, Germany) and Boehringer 
Ingelheim (Vienna, Austria) respectively.  
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After confirmation of target inhibition using western blot (see below), 2000 cells were 
counted and seeded into 100mm cell culture dishes. The following day, cells were 
treated with both drugs at 100nM and 1000nM independently and in combination for 24 
hours before irradiation, untreated cells were used as controls. The drugs were removed 
and culture medium changed for drug free culture medium 24 hours after irradiation, 
and a further 7 days were allowed before colony counting.     
 
Colony Counting:  
Colonies with 50 or more cells were counted as survivors using an automated colony 
counter (GelCount, Oxford Optronics). Each assay was performed using triplicate 
technical replicates and at least three independent experimental replicates were 
performed (unless otherwise specified).  
 
2.3.4 Western Blotting 
The cells of interest were cultured to 80-90% confluence in 100mm culture dishes and 
treated with human recombinant IGF-1 ligand (50nM) (Sigma-Aldrich, St Louis, USA) 
and/or human recombinant EGF ligand (20nM) (Sigma-Aldrich, St Louis, USA) for 20 
minutes. In some cases, cells were also treated with Afatinib or BI836845 for 60 
minutes, before addition of IGF-1 and/or EGF ligand for 20 minutes. Control cells were 
treated with dimethyl sulfoxide (DMSO) (solvent for Afatinib) to match the 
concentration present for each drug tested.  
 
Culture medium was removed and cells washed with ice-cold phosphate buffered saline 
(PBS). Cells were scraped into 1ml of ice-cold PBS, transferred to eppendorf tubes and 
centrifuged at 13,500rpm for 30 seconds at 4°C. The supernatant was removed and cell 
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pellets were snap frozen on dry ice and ethanol. The pellets were immediately used for 
western blotting.  
 
Cell pellets were then re-suspended in radio-immunoprecipitation assay (RIPA) lysis 
buffer (0.1% SDS, 0.5% sodium deoxycholate, 1% Triton, 150mM NaCl, 1mM EDTA 
and 20mM Tris pH7.5, supplemented with protease inhibitor cocktail (Roche©, West 
Sussex, UK), 1.5mM Pefabloc SC plus (Roche©, West Sussex, UK) and phosphatase 
inhibitor complex II and III (Sigma-Aldrich, St Louis, USA)). The lysates were 
incubated on ice for 30 minutes before centrifuging at 13,5000rpm at 4°C for 15 
minutes. The lysates were used for protein assay (PierceTM BCA Protein Assay Kit, 
ThermoFisher Scientific, Loughborough, UK) to determine the volume required for 30-
40 µg of protein. Equivalent amounts of protein were mixed with Laemelli sample 
buffer (70mM Tris pH6.8, 5% β-mercaptoethanol, 40% glycerol, 3% SDS and 0.05% 
bromphenol blue), denatured at 95°C for 3-5 minutes and loaded onto 8% 
polyacrylamide gels for SDS polyacrylamide gel electrophoresis (SDS-PAGE). Protein 
transfer to a nitrocellulose membrane (Hybond C extra, Amersham Biosciences) was 
achieved using TransBlot® Turbo Transfer System with TransBlot® Turbo Transfer 
buffer solution (Bio-Rad, Hertfordshire, UK).    
 
Membranes were blocked in 5% non-fat dairy milk for 1 hour at room temperature, and 
primary antibody applied for 60 minutes at room temperature. A summary of the 
primary and secondary antibodies used including solvents and concentrations is 
provided in Table 2-1.  Following three 5 minute washes with Tris-Buffered Saline and 
0.1% Tween (TBS-T), bound antibody was detected by incubating with goat anti-rabbit 
or goat anti-mouse secondary antibodies conjugated to horseradish peroxidase (DAKO, 
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Ely, UK) in blocking buffer at room temperature for 30 minutes. Three further washes 
with TBS-T were performed and proteins detected with Enhanced Chemiluminescence 






targeted Manufacturer Concentration Solvent 
pEGFR 2236 Tyr 1068 Cell Signalling Technology ® 1:500 5% BSA 
EGFR 2232 n/a Cell Signalling Technology ® 1:1000 5% SM 
pIGF-1R 3024 Tyr 1135/1136 Tyr 1150/1151 
Cell Signalling 
Technology ® 1:500 5% BSA 
IGF-1R 3027 n/a Cell Signalling Technology ® 1:1000 5% SM 
pAKT 4060 n/a Cell Signalling Technology ® 1:500 5% BSA 
AKT 9272 n/a Cell Signalling Technology ® 1:1000 5% BSA 
pERK 9101 n/a Cell Signalling Technology ® 1:1000 5% BSA 
ERK 4695 n/a Cell Signalling Technology ® 1:2000 5% BSA 
β-tubulin T4026 n/a Sigma Aldrich 1:2000 5% SM 
PTEN 9556 n/a Cell Signalling Technology ® 1:2000 5% BSA 
 
Secondary 
Antibody Product code Manufacturer Species Concentration Solvent 
pEGFR 7076 Cell Signalling Technology ® Mouse 1:10,000 5% SM 
EGFR 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
pIGF-1R 7074 Cell Signalling Technology ® Rabbit 1:2000 5% SM 
IGF-1R 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
pAKT 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
AKT 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
pERK 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
ERK 7074 Cell Signalling Technology ® Rabbit 1:5000 5% SM 
β-tubulin 7076 Cell Signalling Technology ® Mouse 1:5000 5% SM 
PTEN 7076 Cell Signalling Technology ® Mouse 1:5000 5% SM 
 
Table 2-1: List of primary and secondary antibodies utilised for Western Blotting 
 
Abbreviations: BSA, Bovine Serum Albumin; SM, skimmed milk.  
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2.3.5 Statistical Analysis 
All statistical analyses were pre-determined and performed using Prism 7 for Mac OS X 
(© 1994-2015 GraphPad Software, Inc). Radio sensitivity was determined by 
calculating the dose of irradiation required to suppress survival to 50% of irradiated 
controls (SF50) with 95% confidence intervals.  The dose enhancement ratio (DER) at 
2Gy and 5 Gy (where specified) was calculated when comparing the effects of receptor 
inhibition. This was taken as the ratio of control cells surviving at 2Gy or 5Gy vs. 
treated cells. Results of clonogenic survival assays were assessed using multiple t-tests 
(Holm-Sidak correction) or one-way ANOVA (Tukey’s test) if >2 groups were 


















2.4.1 Establishing Baseline Characteristics of SQ20B and BICR18 cells 
Western blots were performed to establish the baseline characteristics of SQ20B and 
BICR18 cells (Figure 2-2). The aim was to characterise the cell lines, confirm 
appropriate activation of targeted receptors, identify suitable targets for inhibition and 











Figure 2-2: Western blot comparing parental SQ20B and BICR18 cells  
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor.  
 
Equivalent amounts of protein were utilised to perform western blot to compare the relative expression of 
total and phosphorylated IGF-1R, EGFR, AKT, ERK and β-tubulin between parental SQ20B and parental 
BICR18 cells. Presented is a representative result from three independent assays with equivalent protein 
loading evidenced by equal β-tubulin expression. SQ20B and BICR18 cells were treated with IGF-1 














































































Total and phosphorylated IGF-1R, EGFR, AKT and ERK were compared with and 
without the presence of IGF-1 and EGF ligand. SQ20B cells expressed IGF-1R and 
EGFR, whilst BICR18 expressed only IGF-1R.  
 
In SQ20B cells, IGF-1 resulted in activation of IGF-1R and downstream effectors AKT 
and ERK. EGF ligand resulted in phosphorylation of EGFR and downstream effectors 
AKT and ERK. There was also weak activation of IGF-1R; this relationship was later 
explored in detail (see section 2.4.5). In this cell line, EGF ligand had a greater effect 
on ERK phosphorylation than IGF-1.  
 
In BICR18 cells, IGF-1 resulted in activation of IGF-1R and downstream effectors AKT 
and ERK. The effects of EGF-ligand on EGFR phosphorylation could not be assessed, 
as this receptor was not detected. However, EGF ligand stimulation resulted in 
activation of ERK. The signalling pathway for this effect remained undetected, but may 
have related to an alternative ErbB family receptor e.g. Her2. Subsequent western 
blotting for this receptor was unsuccessful.  
 
The results confirmed the presence of EGFR and IGF-1R signalling cascades in SQ20B 
cells and IGF-1R signalling in BICR18 cells. It also meant there was biological 
evidence to support the existence of previously described IGF-1R and EGFR pathways 





2.4.2 Testing Effects of Combined IGF-1R and EGFR Inhibition in Laryngeal Cancer 
Cells.  
Next, western blotting was performed to determine the effects of IGF-1R and EGFR 
inhibition on BICR18 and SQ20B cells. Both cell lines were treated with mono therapy 
(BI836845 or Afatinib) (Figure 2-3 and 2-4) and combination therapy 
(BI836845/Afatinib) (Figure 2-5). Although EGFR had not been detected in BICR18 
cells, the activation of ERK in response to EGF-ligand suggested the presence of 
another ErbB family receptor. Given that Afatinib is known to affect this receptor 
family[113], the decision was made to investigate the effects of this drug on BICR18 
cells also. The aim was to confirm target and downstream inhibition with both drugs, 


















Figure 2-3: Western Blot comparing effects of IGF-1R and EGFR inhibition in 
BICR18 cells 
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1. 
 
Western blotting to compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, 
ERK and β-tubulin between BICR18 cells treated with BI836845, Afatinib or equivalent volume of solvent 
(dimethyl sulfoxide).  Cells were lysed, and equal concentrations of protein used for western blotting as 
previously described (see methods). Presented is a representative result from three independent assays 
with equivalent protein loading evidenced by equal β-tubulin expression. These results demonstrate direct 
and downstream target inhibition of IGF-1R with BI836845 at 100nM and 1000nM. There is also dose 
dependant inhibition of AKT phosphorylation with increasing doses of BI836845 (100nM and 1000nM).  
Afatinib has no effect on IGF-1R, however it appears to cause dose dependant inhibition of ERK 





































































































Figure 2-4: Western Blot comparing effects of IGF-1R and EGFR inhibition in SQ20B 
cells 
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor. 
 
Western blotting to compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, 
ERK and β-tubulin between SQ20B cells treated as in figure 2-3. Presented is a representative result 
from three independent assays with equivalent protein loading evidenced by equal β-tubulin expression. 
BI836845 (10nM, 100nM and 1000nM) inhibits pIGF-1R but not its downstream targets (pERK or 






































































































Figure 2-5: Western Blot comparing effects of IGF-1R and EGFR combined inhibition 
on BICR18 and SQ20B cells 
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor. 
 
Western blot to compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, ERK 
and β-tubulin between SQ20B and BICR18 cells treated with both BI836845 and Afatinib at 100nM in the 
presence of both IGF and EGF ligand (as in legend for figure 2-3). Presented is a representative result 
from three independent assays with equivalent protein loads evidenced by equal β-tubulin expression. In 
SQ20B cells, combined treatment was effective at inhibiting pIGF-1R, pEGFR, pAKT but not pERK. 




























































































In BICR18 cells (Figure 2-3 and 2-5), BI836845 (10nM) did not affect IGF-1R 
phosphorylation. BI836845 (100nM) resulted in decreased phosphorylation of IGF-1R 
and AKT, whilst BI836845 (1000nM) also reduced ERK phosphorylation. Afatinib 
(10nM, 100nM, 1000nM) did not affect phosphorylation of IGF-1R or AKT but 
reduced ERK phosphorylation at 100nM and 1000nM. Combination treatment at 
100nM resulted in decreased IGF-1R, AKT and ERK phosphorylation.     
 
In SQ20B cells (Figure 2-4 and 2-5), which expressed both IGF-1R and EGFR, 
BI836845 reduced IGF-1R phosphorylation but did not affect AKT or ERK activation. 
Afatinib decreased EGFR and AKT phosphorylation from 10nM, whilst ERK activation 
was only reduced at 100nM and 1000nM. EGF ligand was noted to result in activation 
of IGF-1R suggesting the presence of receptor ‘cross-talk’. Combination treatment was 
effective at inhibiting IGF-1R, EGFR, AKT phosphorylation but not ERK.  
 
Thus, in both cell lines BI836845 and Afatinib (100nM and 1000nM) demonstrated an 
effect on IGF-1R and EGFR signalling. These concentrations were selected for 
subsequent CSAs aimed at determining the effects of each drug alone and in 
combination on cell survival and as a radio-sensitizing agent.  
 
CSAs were performed to compare the effects of single and combined drug treatment in 








Figure 2-6a: Clonogenic survival assay to assess effects of Afatinib and BI836846 
alone and in combination on BICR18 cells surviving at 0Gy after 9 days (BICR18 cells 
vs. BICR18 cells treated with Afatinib and/or BI836845). 
 
Abbreviations: Af, Afatinib; BI, BI836845   
 
For each drug combination tested, 2000 BICR18 cells were seeded into 100mm cell culture dishes and 
either drug solvent or drug treatment applied. 24 hours later, cells were treated with varying doses of 
radiotherapy (0-10Gy). The culture medium was replaced 24 hours later and cells allowed a further 7 
days to grow before colony counting. This graph is a representative CSA from 2 independent assays 
performed in triplicate (except at 1000nM, which was only performed once) to compare colony survival 
in BICR18 cells treated with increasing doses of BI836845 and Afatinib as mono and combined therapy 
in the absence of radiation. There were significantly fewer colonies surviving at 9 days in cells treated 
with Afatinib 1000nM when compared to parental cells treated with Afatinib 100nM. Bars represent the 
number of colonies surviving as a proportion of parental cells + standard error of the mean (SEM). * 



















































































































































































































































































































































































































































































































Figure 2-7a: Clonogenic survival assay to show percentage of colonies surviving at 
0Gy after 9 days (SQ20B cells vs. SQ20B cells treated with Afatinib and/or BI836845). 
 
Abbreviations: Af, Afatinib; BI, BI836845   
 
This graph is a CSA from an assay performed with triplicate technical replicates, to compare baseline 
colony survival in SQ20B cells treated with increasing doses of BI836845 and Afatinib as mono and 
combined therapy in the absence of radiation (treatments were performed as described in Figure 2-6a). 
There were significantly fewer colonies surviving at 7 days in cells treated with Afatinib 100nM, Afatinib 
1000nM and Afatinib/BI836845 100nM when compared to control-treated cells. Combined treatment 
with Afatinib and BI836845 had a greater effect on survival than Afatinib alone. Bars represent the 
number of colonies surviving as a proportion of parental cells + standard error of the mean (SEM). * 























































































































































































































































































































































































































































































































































There was no difference in cell survival in BICR18 cells treated with 10-1000nM 
BI836845 or 100nM Afatinib, while Afatinib 1000nM reduced the mean colony count 
by 16% (p=0.046) compared with solvent treated cells (Figure 2-6a). When BICR18 
cells were treated with single and combined drug therapy alongside increasing doses of 
radiation there was no difference in terms of SF50, DER at 2Gy, or survival at each 
radiotherapy dose. The results suggested that BICR18 cells were not radiosensitized by 
BI836845 or Afatinib alone or in combination (Figure 2-6b).  
 
In SQ20B cells treatment with Afatinib 100nM, Afatinib 1000nM and 
BI836845/Afatinib 100nM was associated with a 35% (p=0.004), 74% (p=0.0001) and 
67% (p=0.0001) reduction in baseline colony survival at 0Gy, whilst BI836845 alone 
had no effect. There were 32% (p=0.0.007) fewer colonies in cells treated with 
combined BI836845 and Afatinib at 100nM when compared to Afatinib 100nM alone 
(Figure 2-7a). However, this combined effect was inferior to the reduction in cell 
survival achieved by Afatinib at 1000nM.  
 
In SQ20B cells treated with Afatinib alone and in combination with BI836845 there was 
evidence of radiosensitization, with reduction in SF50 and increase in DER at 2Gy. 
Treatment with Afatinib (100nM) was more effective than BI836845 at 1000nM but not 
at 100nM, and Afatinib (100nM) alone was as effective as Afatinib and BI836945 






2.4.3 Effects of Repeated Irradiation on Laryngeal Cancer Cells. 
Both cell lines were repeatedly irradiated to assess changes induced by clinically used 
doses of radiation (see methods). Western blots were performed on parental and 
repeatedly irradiated cells to determine total and phosphorylated IGF-1R, EGFR and 













Figure 2-8: Western Blot comparing BICR18, 55GyBICR18 and 60GyBICR18 cells 
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1 
 
Western blotting to compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, 
ERK and β-tubulin between parental BICR18 and repeatedly irradiated 55GyBICR18 and 60GyBICR18 
cells. Presented is a representative result from three independent assays (performed as in Figure 2-2) 
with equivalent protein loading evidenced by equal β-tubulin expression They demonstrate up regulation 
of baseline total IGF-1R and increased phosphorylation of AKT and ERK in response to IGF ligand in 
55GyBICR18 and 60GyBICR18. They also suggest EGF ligand stimulation associates with 
phosphorylation of AKT in 55GyBICR18 and ERK in 55GyBICR18 and 60GyBICR18; this is not seen in 




















































































Figure 2-9: Western Blot to compare SQ20B and 55GySQ20B cells. 
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor. 
 
Western blotting to compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, 
ERK, PTEN and β-tubulin between parental (SQ20B) and repeatedly irradiated cells (55GySQ20B).  
Presented is a representative result from three independent assays (performed as in Figure 2-2) with 
equivalent protein loading evidenced by equal β-tubulin expression. Exposure artefact is noted when 
interpreting phosphorylation of EGFR. These results demonstrate higher levels of EGFR, IGF-1R, ERK 
and lower PTEN in repeatedly irradiated cells (55GySQ20B). IGF-1 and EGF ligand stimulation has a 
greater effect on phosphorylation of IGF-1R and EGFR in irradiated cells when compared to parental 

















































































Parental BICR18 cells expressed IGF-1R, AKT, and ERK but not EGFR. IGF-1 
stimulation was associated with phosphorylation of IGF-1R, AKT and ERK. EGF 
ligand stimulation had no effect on these targets. These results were similar to those 
seen earlier (Figure 2-2); however on this occasion EGF ligand was shown to activate 
ERK phosphorylation, the cause for this was unclear.  
 
When compared, both irradiated BICR18 cell lines (55GyBICR18 and 60GyBICR18) 
expressed higher total IGF-1R than parental cells. IGF-1 had a greater effect on 
phosphorylation of IGF-1R in 55GyBICR18. IGF-1 also had a similar effect on 
phosphorylation of AKT and ERK in 55GyBICR18 and 60GyBICR18.  EGF ligand 
resulted in phosphorylation of AKT in 55GyBICR18 and ERK in both 55GyBICR18 
and 60GyBICR18, these effects were not seen in the parental cell line (Figure 2-8).  
 
SQ20B parental cells expressed EGFR, IGF-1R, AKT, and ERK as previously seen (in 
Figure 2-2). IGF ligand stimulation resulted in phosphorylation of IGF-1R, whilst EGF 
ligand was associated with phosphorylation of EGFR and ERK. These results were 
again similar to those previously seen (Figure 2-2). Repeatedly irradiated cells 
(55GySQ20B) expressed higher levels of EGFR and IGF-1R when compared to 
parental cells (Western blots of 60GySQ20B failed due to technical issues and time 
constraints meant repeats were not possible). IGF-1 and EGF ligand had a greater effect 
on phosphorylation of IGF-1R and EGFR in irradiated cells when compared to parental 
cells. The irradiated cells also showed higher basal and IGF-1 induced AKT 
phosphorylation, and higher phosphorylated ERK than parental cells. In an attempt to 
identify reasons for elevated AKT phosphorylation, PTEN expression was assessed. 
This appeared to be lower in irradiated cells (Figure 2-9).   
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Next, clonogenic survival assays were performed to determine baseline survival for 
each parental and irradiated cell line (Figure 2-10a and 2-11a). Baseline colony counts 
in the absence of radiation were significantly lower for irradiated cells irrespective of 
irradiation regime or cell line (p<0.05). Specifically, baseline colony counts were 23% 
lower (p=0.004) for 55GyBICR18 and 60GyBICR18 when compared to BICR18. In 
irradiated SQ20B cells, baseline survival was low (<30%); to overcome this 10,000 
cells of each irradiated cell line were seeded and the assay repeated. The subsequent 
reduction in colony counts were less obvious but still significant. They were 10% 
(p=0.015) and 19% (p=0.0004) lower in 55GySQ20B and 60GySQ20B when compared 
to SQ20B. Pooled analysis, confirmed reduced baseline survival for irradiated SQ20B 
cells.  
 
Next, the relative radio sensitivity of each parental and irradiated cell line was assessed 
(Figure 2-10b and 2-11b). The SF50 for 55GyBICR18 was higher than that of 
60GyBICR18 and BICR18 (4.4 vs. 3.7 vs. 4.0) but the DERs at 2Gy were similar. At 
8Gy both 60GyBICR18 and 55GyBICR18 had significantly higher survival rates 
(p=0.007 and p=0.002) whilst 60GyBICR18 also had improved survival at 10Gy 
(p=0.001). The results suggested a trend towards radiotherapy resistance in repeatedly 
irradiated laryngeal cancer cells 55GyBICR18 and 60GyBICR18.   
 
Radiation survival assays in SQ20B cells indicated radioresistance in 55GySQ20B cells, 
with a higher SF50 and lower DER at 2 Gy than 60GySQ20B and SQ20B cells (4.3 and 
0.89 vs. 2.5 and 1.2 vs. 3.3 and 1.0) (Figure 2-11b). Compared with parental cells, 
60GySQ20B cells were more resistant at 2Gy (p=0.005), whilst 55GySQ20B cells were 
more resistant at 2, 4, 6, and 8Gy (p<0.002). Thus, there was evidence to suggest a 
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radiotherapy resistant phenotype in the repeatedly irradiated laryngeal cancer cell line 
55GySQ20B.   
 
To test whether apparent radioresistance or changes in expression were due to a later 
passage of the irradiated cell line, CSAs were performed to compare early and late 
passage BICR18 and SQ20B cells (Figure 2-10c and 2-11c). The results demonstrated 
no statistically significant difference in relative radiosensitivity when comparing early 
and late passage BICR18 and SQ20B cells.  
 
Figure 2-10a: Clonogenic survival assay to show percentage of colonies surviving at 
0Gy after 7 days (BICR18 vs. 55GyBICR18 vs. 60GyBICR18).  
 
Abbreviations: Gy, Gray; %, percentage. 
 
For each cell line tested, 2000 cells were seeded into 100mm cell culture dishes. 24 hours later, cells 
were treated with varying doses of radiotherapy (0-10Gy). Cells were allowed a further 7 days before 
colony counting. Presented here is a representative CSA from one of 4 independent assays performed in 
triplicate to compare baseline colony survival in BICR18, 55GyBICR18 and 60GyBICR18 cells with no 
treatment at 7 days. The table presents the mean of all 4 assays. There were significantly fewer colonies 
surviving at 7 days in cells previously treated with both radiotherapy regimes (55Gy20Fr and 60Gy30Fr) 
when compared to parental cells. Bars represent number of colonies surviving as a proportion of 


































































































































































































































































































































































































































































































































































Figure 2-10c: Clonogenic survival assay comparing early vs. late passage BICR18 cells  
 
Abbreviations: Gy, Gray; %, percentage; CI, Confidence interval;SF50, standard dose fraction for 50% 
cell survival; DER, dose enhancement ratio at 2Gy.  
 
CSA from 3 independent assays performed in triplicate to compare colony survival in early vs. late 
passage BICR18 cells (10 passage difference between early and late cells). The table presents the mean 
of all 3 assays. The graph demonstrates the percentage of colonies surviving for each cell line with 
increasing doses of irradiation (0-10Gy). There was no statistically significant difference (multiple t-
tests) in overall and colony survival at each radiation dose. Points represent the number of surviving 









































Figure 2-11a: Clonogenic survival assay to show percentage of colonies surviving at 
0Gy after 7 days (SQ20B vs. 55GySQ20B vs. 60GySQ20B).  
 
Abbreviations: Gy, Gray; %, percentage. 
 
Representative CSA from 4 independent assays (treated as in Figure 2-10a) performed in triplicate to 
compare baseline colony survival in non-irradiated SQ20B, 55GySQ20B and 60GySQ20B cells. In the 
presented assay, 10,000 cells of 55GySQ20B and 60GySQ20B cells were seeded, due to the 
comparatively poor survival at baseline noted for irradiated cells. The table presents the mean of the 3 
assays performed when 2000 cells were seeded for each cell line. There were significantly fewer colonies 
surviving at 7 days in cells previously treated with both radiotherapy regimes (55Gy20Fr and 60Gy30Fr) 
when compared to parental cells. There were significantly fewer surviving colonies in cells treated with 
60Gy30Fr when compared to those receiving 55Gy in 20Fr. This difference was not noted in pooled 
analysis. Bars represent the number of colonies surviving as a proportion of parental cells + standard 












































    
 
Figure 2-11b: Clonogenic survival assay comparing SQ20B, 55GySQ20B and 
60GySQ20B cells.  
 
Abbreviations: Gy, Gray; %, percentage; CI, Confidence interval;SF50, standard dose fraction for 50% 
cell survival; DER, dose enhancement ratio at 2Gy.  
 
Representative CSA from 4 independent assays performed in triplicate to compare colony survival in 
SQ20B, 55GySQ20B and 60GySQ20B cells treated with increasing doses of irradiation. The graph 
demonstrates the percentage of colonies surviving for each cell line with increasing doses of radiotherapy 
(0-10Gy). The table presents the mean of all 4 assays. Repeatedly irradiated 55GySQ20B cells had a 
higher SF50 and lower DER at 2Gy when compared to parental cells.  55GySQ20B appeared to 
demonstrate a radiotherapy resistant phenotype. Points represent the number of surviving colonies as a 
proportion of untreated cells of the same type  + standard error of the mean (SEM). * marks a 


















































Figure 2-11c: Clonogenic survival assay comparing early vs. late passage SQ20B cells 
 
Abbreviations: Gy, Gray; %, percentage; CI, Confidence interval;SF50, standard dose fraction for 50% 
cell survival; DER, dose enhancement ratio at 2Gy.  
 
Representative CSA from 3 independent assays performed in triplicate to compare colony survival in 
early vs. late passage SQ20B cells (10 passage difference between early and late cells). The table 
presents the mean of all 3 assays. The graph demonstrates the percentage of colonies surviving for each 
cell line with increasing doses of radiotherapy (0-10Gy). There was no statistically significant difference 
(multiple t-tests) in overall and colony survival at each radiation dose. Points represent the number of 




2.4.4 Testing Effects of Combined IGF-1R and EGFR Inhibition in Repeatedly 
Irradiated Laryngeal Cancer Cells.  
Following repeated irradiation, and its effect on IGF-1R and EGFR (SQ20B cells only) 
signalling, parental and irradiated cells were treated with BI836845 and Afatinib.  
 
Western blots were conducted to assess the effects of Afatinib and BI836845 alone and 
in combination on BICR18 and 55GyBICR18 cells (Figure 2-12a). IGF-1R up 
regulation was again noted in the irradiated cells. Both drugs demonstrated target 
inhibition as previously seen (Figure 2-3, 2-4, 2-5). In 55GyBICR18 cells ERK 
Early	passage	vs.	late	SQ20B	
	





















phosphorylation appeared to be more sensitive to inhibition, being inhibited by 
BI836845 alone and in combination with Afatinib. Afatinib alone did not have this 
effect. In contrast, the parental cells showed no ERK inhibition in response to 
BI836845, and minor reduction upon Afatinib treatment (Figure 2-12a), consistent with 
previously described results (Figure 2-3).  
 
CSAs were performed to compare cell survival in response to single and combined drug 
treatment in the absence of irradiation (Figure 2-12b). Parental BICR18 cells showed 
no difference in survival when treated with BI836845 or Afatinib at 100nM (as in 
Figure 2-6a). In 55GyBICR18 cells each drug alone had no statistically significant 
effect on survival, however combined treatment resulted in a 28% lower colony count, 
which was significant when compared with untreated controls (p=0.032). The relative 
radiosensitivity of BICR18 and 55GyBICR18 cells with single and combined treatment 
was also tested using CSA (Figure 2-12c). There was no detectable difference in 
response to irradiation when comparing cell lines or treatments at the doses tested.  
 
SQ20B and 55GySQ20B cells were also compared for baseline survival when treated 
with both drugs in the absence of irradiation (Figure 2-13a). BI836845 alone did not 
inhibit cell survival in the parental or irradiated cells. Cell survival was significantly 
reduced in both SQ20B and 55GySQ20B cell lines when treated with Afatinib alone or 
in combination with BI836845. When relative survival in SQ20B cells and 55GySQ20B 
cells treated with both drugs was compared, it was apparent that 55GySQ20B cells were 
significantly more sensitive to combined IGF-1R/EGFR inhibition (p=0.0001) (Figure 
2-13a). This suggested a potential advantage to combination treatment in the repeatedly 
irradiated cells with IGF-1R up regulation.     
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Radiation survival assays were then performed to determine whether mono or 
combination therapy was able to influence radiosensitivity of the parental and 
repeatedly irradiated SQ20B laryngeal cancer cell lines (Figure 2-13b). As before (in 
Figure 2-7b), BI836845 was ineffective, and parental cells were only modestly 
radiosensitized by Afatinib alone and with BI836845. The proportionate colony counts 
for SQ20B and 55GyS20B at 5Gy and 10Gy were not significantly different 











Figure 2-12a: Western blot to assess effects of BI836845 and Afatinib on BICR18 cells 
(BICR18 vs. 55GyBICR18).  
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor. 
 
Western blots were used to compare the relative expression of total and phosphorylated IGF-1R, AKT, 
ERK, and β-tubulin between parental (BICR18) and repeatedly irradiated cells (55GyBICR18) in 
response to IGF and EGFR inhibition (cells treated as per Figure 2.3).  Presented is a representative 
result from two independent assays. Exposure artefact is noted when interpreting AKT. These results 
demonstrate higher levels IGF-1R and reduced pERK in response to BI836845 100nM and 










































































































Figure 2-12b: Clonogenic survival assay to show percentage of colonies surviving at 
0Gy after 9 days (BICR18 cells vs. 55GyBICR18 cells treated with Afatinib and/or 
BI836845). 
 
Abbreviations: Af, Afatinib; BI, BI836845   
 
CSA from a single assay performed in triplicate to compare baseline colony survival in BICR18 and 
55GyBICR18 cells treated with BI836845 and Afatinib as mono and combined therapy in the absence of 
radiation (cells treated as per Figure 2.6a). There were significantly fewer colonies surviving at 9 days in 
55GyBICR18 cells treated with Afatinib/BI836845 100nM when compared to 55GyBICR18 cells. There 
were no other significant differences in colony survival detected when comparing the remaining groups. 
These results suggested a potential benefit for combination treatment over mono therapy. Bars represent 
the number of colonies surviving as a proportion of parental cells + standard error of the mean (SEM). * 

































































































Figure 2-12c: Clonogenic survival assay comparing BICR18 cells vs. 55GyBICR18 
cells treated with Afatinib and/or BI836845 with increasing doses of radiotherapy 
 
Abbreviations: Af, Afatinib; BI, BI836845; DER, dose enhancement ratio; Gy, Gray; SF50, standard dose 
fraction for 50% cell survival  
 
CSA from a single assay performed in triplicate to compare colony survival in BICR18 and 55GyBICR18 
cells treated with Afatinib, BI836845 or both alongside increasing doses of radiotherapy (treatments 
given as in Figure 2-6a). Drug treatment did not enhance the effects of radiotherapy in parental cells. 
There was no difference in colony count, SF50 or DER at 5Gy when comparing cell lines and treatment 
regimes. Points represent the number of surviving colonies as a proportion of untreated cells of the same 

































































Figure 2-13a: Clonogenic survival assay to show percentage of colonies surviving at 
0Gy after 9 days (SQ20B cells vs. 55GySQ20B cells treated with Afatinib and/or 
BI836845). 
 
Abbreviations: Af, Afatinib; BI, BI836845   
 
CSA from a single assay performed (as in Figure 2-6a) in triplicate to compare baseline colony survival 
in SQ20B and 55GySQ20B cells treated with BI836845 and Afatinib as mono and combined therapy in 
the absence of radiation. There were significantly fewer colonies surviving at 9 days in parental cells 
treated with Afatinib 100nM and Afatinib/BI836845 100nM when compared to parental control cells. 
There was a similar result for 55GySQ20B cells. Although combination treatment appeared better in both 
cell lines when compared to Afatinib alone the difference was not statistically significant. There were 
significantly fewer colonies surviving for 55GySQ20B cells treated with combined therapy when 
compared to parental cells receiving the same treatment (p=0.0001). These results suggested a potential 
benefit for combination treatment over mono therapy in cells with up regulation of IGF-1R. There were 
no other significant differences in colony survival detected when comparing the remaining groups.  Bars 
represent the number of colonies surviving as a proportion of parental cells + standard error of the mean 


























































































Figure 2-13b: Clonogenic survival assay comparing SQ20B cells vs. 55GySQ20B cells 
treated with Afatinib and/or BI836845 with increasing doses of radiotherapy 
 
Abbreviations: Af, Afatinib; BI, BI836845; DER, dose enhancement ratio; Gy, Gray; SF50, standard dose 
fraction for 50% cell survival 
 
CSA from a single assay performed in triplicate to compare colony survival in SQ20B and 55GySQ20B 
cells treated with Afatinib, BI836845 or both alongside increasing doses of radiotherapy (treatments 
given as in Figure 2-6a). The SF50 was lower for both cell lines when treated with Afatinib alone and in 
combination with BI836845 in comparison to no treatment or treatment with BI836845 alone. The DERs 
at 2Gy and colony counts at each radiotherapy dose remained similar irrespective of treatment regime. 
Points represent the number of surviving colonies as a proportion of untreated cells of the same type  + 






















































2.4.5 Detecting Cross-Talk in SQ20B cells.  
In SQ20B cells, EGF ligand was noted to result in increased IGF-1R phosphorylation 
(Figure 2-4). This potential relationship suggesting cross talk between the two receptors 
was explored using western blotting (Figure 2-14).  Stimulation with EGF ligand 
resulted in phosphorylation of IGF-1R, but IGF-1 did not have this effect on EGFR. 
Afatinib did not block this phosphorylation, and when BI836845 was used alongside 
EGF ligand in an attempt to inhibit any IGF ligand mediated IGF-1R activation, there 
was no effect on IGF-1R, AKT or ERK phosphorylation. These results suggested an 
alternative mechanism for signalling to IGF-1R, for example through a co-receptor as 










Figure 2-14: Investigating cross-talk between EGFR and IGF-1R in SQ20B cells  
 
Abbreviations: MW, molecular weight; kDa, kilodaltons; p, phosphorylated; EGF, epidermal growth 
factor; IGF-1, insulin like growth factor type 1, IGF-1R, insulin like growth factor receptor type 1; EGFR, 
epidermal growth factor receptor. 
 
These western blots compare the relative expression of total and phosphorylated IGF-1R, EGFR, AKT, 
ERK and β-tubulin in SQ20B cells in the presence of IGF-ligand, EGF ligand and Afatinib and 
BI836945. Presented is a representative result from three independent blots (performed as per Figure 2-
3). Seen here is evidence of ‘cross-talk’ between the IGF-1R and EGFR. EGF ligand is seen to result in 
phosphorylation of IGF-1R. This effect is not inhibited by the use of Afatinib (EGF RTK) or BI836845.  
These results suggest EGF ligand in this cell line may directly result in stimulation of IGF-1R without the 































































































































This study aimed to create an in vitro model of radiotherapy resistant laryngeal cancer 
cells using repeated irradiation. The overall aim was to compare expression and 
activation of EGFR, IGF-1R and communal downstream targets between parental and 
irradiated cells, and to determine whether irradiated or radiotherapy resistant cells 
responded differently to inhibition of the IGF and EGF axes.    
 
Two different laryngeal cancer cell lines, BICR18 and SQ20B were used. Western blots 
showed that BICR18 cells expressed IGF-1R but not EGFR, whilst SQ20B cells 
expressed both. This was an unexpected result, as EGFR is frequently detected in 
HNSCC [100], as found in our earlier study (Chapter 1). LSCC cells were treated with 
two different irradiation regimens (55Gy20Fr and 60Gr30Fr) commonly used in clinical 
practise in an attempt to induce a radiotherapy resistant phenotype.  
 
2.5.1 Developing a Model of Radiation Resistance in Laryngeal Cancer Cells 
Repeatedly irradiated BICR18 cells showed a minor trend towards radiotherapy 
resistance (Figure 2-10b). For SQ20B cells repeated irradiation resulted in a 
radiotherapy resistant phenotype, with a higher SF50 (4.3 vs. 3.3) and lower DER at 2Gy 
(0.89 vs. 1.0) in 55GySQ20B cells when compared to parental cells (Figure 2-11b).  
 
Radiotherapy resistant cell lines have previously been developed to study a number of 
different solid organ tumours, including oesophageal [114], prostate [115], breast [116] 
and oral cancer [117]. A variety of protocols using repeated radiation exposure have 
been described, differing in overall total dose, length of treatment and recovery time 
[118]. Studies have utilised an average total dose of 40-60Gy [118] with treatment 
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duration ranging from 5 days [115] to 6 years [119] and 12-14 days recovery time after 
final treatment fraction. Lee et al (2013) [117] used a total of 60Gy to induce 
radiotherapy resistance in oral squamous cell carcinoma cell lines. As with our study, 
they based the dosing regime on current clinical practise. They concluded that the ideal 
study of radiation resistance in head and neck cancer should closely resemble a ‘real 
clinical setting’. Given that most head and neck cancers are treated with 2-3Gy fractions 
up to a total of 50-70Gy, they selected a total dose of 60Gy. They did not specify the 
length of treatment and recovery time provided to cells. In the current study, 
radiotherapy regimes matched two protocols commonly used in our hospital for the 
treatment of LSCC. Cells were treated for 5 days followed by 2 days rest for 4 to 6 
weeks, and 14 days were given for recovery before further investigation. Whilst Lee et 
al (2013) [117] were able to induce radiotherapy resistance using this technique in each 
of their cell lines, we were only able to do so with one of our cell lines. The failure to 
establish a radiotherapy resistant phenotype in BICR18 cells may have related to the 
radiation regime utilised or the nature of the cell line itself. The lack of EGFR 
expression in the BICR18 cells used may have been a factor.   
 
Cell lines are susceptible to genetic alterations over time that may not necessarily relate 
to radiation. For this reason the use of a passage matched parental cell line is useful as a 
control [120]. Whilst this allows for comparisons between parental and treated sub line 
cells, it does not account for potential changes in global gene expression that may occur 
with age[121]. This is only possible if comparisons are made with the original early 
passage cell line. BICR18 cells have previously been reported to express EGFR[122], 
the lack of its expression within our cells could be a result of genetic alterations over 
time. In an attempt to avoid missing further genetic alterations that may have impacted 
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on the radio sensitivity of BICR18 and SQ20B cells, both early and late passage 
parental cells were tested. The relative radio-sensitivity of these cells was compared 
(Figure 2-10c and 2-11c). There was no difference in radio-sensitivity between early 
and late stage parental cells; a detected difference between the parental and treated cells 
was therefore likely a result of repeated irradiation.  
 
It is important to note that any conclusions based on irradiated models developed in 
vitro using these methods may be cell line specific, giving limited clinical applicability. 
This study is clearly limited by this fact. Nonetheless published data has suggested 
common survival advantages amongst radiotherapy resistant sub-cell lines [118]. These 
include increased proliferative capacity, modified cell cycle distribution, increased 
ability to repair DNA damage and reduced oxidative stress and apoptosis in response to 
radiation [118]. Although each of these factors may be measured individually, CSA is 
considered the gold standard test for determining radiosensitivity and is related to each 
of these factors [123]. In the presented study, CSAs confirmed 55GySQ20B cells to be 
less radiosensitive than parental cells, suggesting the presence of one or more of these 
survival advantages in the repeatedly irradiated cell line 55GySQ20B.    
 
2.5.2 IGF-1R and EGFR in Radiotherapy Resistant Laryngeal Cancer Cells 
Western blots comparing EGFR, IGF-1R and other communal downstream receptor 
targets showed that repeated irradiation resulted in up regulation of total IGF-1R in both 
cell lines and EGFR in SQ20B. Whilst investigating possible causes of enhanced AKT 
activation we also found down regulation of PTEN in radiotherapy resistant laryngeal 
cancer subline 55GySQ20B. PTEN is a tumour suppressor gene whose expression is 
suppressed in up to 30% of HNSCCs [124]. Snietura et al (2012) [125] have previously 
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reported an association between low PTEN expression detected by 
immunohistochemistry and resistance to post operative radiotherapy in HNSCC.  
 
The results shown here suggest that repeated irradiation had the potential to up-regulate 
IGF-1R and EGFR and induce a radiotherapy resistant phenotype in laryngeal cancer 
cell lines.  It was unclear if up regulation of IGF-1R and EGFR was a bystander 
consequence of radiotherapy or the mechanism underlying relative radiotherapy 
resistance; it could have involved both. Although, the failure of BI836845 alone to 
radiosensitize either cell line argues against this. Whilst IGF-1R and EGFR 
overexpression is associated with radiotherapy resistance in HNSCC, with both 
signalling pathways activated in response to radiation [95], our study was the first to 
demonstrate up regulation of IGF-1R in cells subjected to repeated irradiation.  
 
The association between high EGFR expression and radiotherapy resistance has been 
known for over two decades. Sheridan et al (1997) [126] demonstrated a strong 
association between radiotherapy resistance and high levels of EGFR using HNSCC cell 
lines derived from primary tumours. Activation of membranous EGFR results in 
endocytosis and nuclear transfer via importin β-1. Nuclear EGFR has three main 
features distinguishing it from its membranous counterpart.  It can function as a co-
transcription factor and co-regulates cyclin D1, inducible nitric oxide synthase, 
cyclooxygenase-2, aurora kinase A, c-Myc, breast cancer resistant protein and Stat1 
[127-133]. Nuclear EGFR enhances cellular proliferation by phosphorylating 
proliferating cell nuclear antigen. EGFR is also known to enter the nucleus following 
radiation therapy to repair radiation induced DNA damage, and this function is 
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inversely related to patient survival in a number of cancers including oropharyngeal 
cancer [134]. 
 
Whilst not all studies have concurred [135] the overwhelming evidence for up 
regulation of EGFR in radiotherapy resistant HNSCC has led to the development of 
therapies targeting this receptor [136]. The EGFR monoclonal antibody Cetuximab has 
shown some treatment benefit in the context of recurrent or metastatic HNSCC, but 
acquired treatment resistance has limited its use [137].  
 
IGF-1R has been associated with radiotherapy resistance in solid organ tumours, 
including breast [138] and malignant melanoma [74]. In vitro, murine and in vivo 
models have demonstrated up regulation of IGF-1R in radiotherapy resistant cancer 
phenotypes [63,73,74,53]. IGF-1R is thought to play a role in cell proliferation, DNA 
repair and cellular apoptosis. Higher levels of IGF-1R associate with increased cell 
proliferation and inhibition of apoptosis [63]. Clinically in tumours with high IGF-1R 
this could mean that during daily radiotherapy treatments a significant proportion of the 
dose given is used to control cells re-populated from the previous day. High 
proliferative tumours therefore have a poorer prognosis; this has previously been 
described in HNSCC patients [139-141].  
 
The EGFR and IGF-1R receptors are thought to cross-communicate, whereby inhibition 
of one receptor can result in up regulation or activation of the other [51,142,50]. IGF-1R 
up regulation has been associated with resistance to EGFR inhibitors in Ewing sarcoma 
[143]. Given their communal downstream signalling targets (Figure 2-1a) it is logical 
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to hypothesize that a similar mechanism may contribute to resistance to treatments 
targeting EGFR in HNSCC.  
 
2.5.3 Testing IGF-1R and EGFR Inhibition to Overcome Radiotherapy Resistance in 
Laryngeal Cancer Cells 
Afatinib and BI836845 demonstrated both receptor and downstream target inhibition in 
BICR18 and SQ20B parental and irradiated cells. In parental BIRC18 cells there was no 
significant treatment benefit from BI836845 or Afatinib separately or in combination 
with and without radiotherapy. In 55GyBICR18 cells, which demonstrated up 
regulation of IGF-1R, combined EGFR and IGF-1R inhibition appeared to induce a 
significant reduction in cell survival when compared to no treatment, the individual 
drugs being ineffective (Figure 2-12b). However, 55GyBICR18 cells were only 
modestly radioresistant, and were not radiosensitized by IGF-1R and/or EGFR 
inhibition.  
 
In parental SQ20B cells, Afatinib (100nM) alone and in combination with BI836845 
(100nM) limited cell survival (Figure 2-7). BI836845 alone did not effect cell survival 
or radiosensitize cells. In the absence of radiotherapy, Afatinib (100nM) and Afatinib 
with BI836845 (100nM) reduced colony survival by 34.6% and 66.5% respectively. 
The effect of combined treatment was significantly greater (p=0.007), although was not 
significantly different from the effect of Afatinib alone at the higher dose of 1000nM.  
The results were not replicated in radiosensitivity assays, where Afatinib (100nM) alone 
seemed to be as effective as Afatinib with BI836845 (100nM) in radio sensitizing cells 
(Figure 2-7b).  
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The repeatedly irradiated 55GySQ20B cells were relatively radio-resistant (Figure 2-
11b), and here, combined Afatinib and BI836845 (100nM) treatment appeared to be 
more effective than treatment with Afatinib (100nM) alone at inhibiting basal cell 
survival. The treatment effect was greater in irradiated cells with 52.4% survival in 
SQ20B cells vs. 22.9% survival in 55GySQ20B cells (p=0.0001) (Figure 2-13a). 
Whilst baseline colony survival was affected by combined drug treatment, the results 
were not replicated in the presence of radiotherapy. In this cell line, Afatinib enhanced 
radiosensitivity but BI836845 with and without Afatinib did not (Figure 2-13b).  
 
These results suggest that combined drug treatment with Afatinib and BI836845 was 
more effective at suppressing basal cell survival in radiotherapy resistant cells with up 
regulation of IGF-1R and EGFR. However, despite affecting baseline colony survival, 
both treatments alone and in combination were unable to radio-sensitize either cancer 
cell line. This suggests that the IGF-1R up regulation induced by irradiation was not a 
driver of radioresistance.  
 
There is evidence that IGF-1R inhibition can increase radiation sensitivity in some 
HNSCC cell lines [95] and augment the effects of radiotherapy in other solid organ 
tumours [144,74]. Our results did not support this, as BI836845 alone had no effect on 
cell survival or radiosensitivity in either of the two cell lines tested here. This could be 
explained by the fact that BI836845 is an IGF-ligand antibody instead of an IGF-1R 
monoclonal antibody (previously shown to induce radiosensitivity as described by Raju 
et al (2015) [95]). There was clear evidence of receptor cross talk between EGFR and 
IGF-1R in the SQ20B cell line. EGF ligand was shown to activate IGF-1R whilst IGF 
ligand did not have this effect on EGFR. Our results showed that EGF ligand 
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stimulation was associated with phosphorylation of IGF-1R, which was not inhibited by 
the use of BI836845 (Figure 2-14), suggesting an IGF ligand independent effect. In the 
absence of EGF ligand stimulation BI836845 was effective at inhibiting IGF-1R 
phosphorylation. The failure of this drug to induce radio sensitivity in the SQ20B cells 
may have been a result of co-stimulation of IGF-1R via EGFR (or one of its family 
members) without the need for IGF ligand, thus bypassing the effects of BI836845.  
 
In BICR18 cells where EGFR was absent, BI836845 had no effect on cell survival or 
response to radiotherapy, despite confirmation of target inhibition using western blots. 
In this cell line an alternative mechanism may have bypassed the effects of the drug via 
the RAS/ERK pathway. Western blots showed that BI836845 inhibited phosphorylation 
of AKT but not ERK, which may have allowed for ongoing cell proliferation and 
survival along this pathway and explained lack of response to this drug.      
 
The IGF-1R pathway is thought to support resistance to EGFR targeted treatments and 
so combined receptor inhibition is expected to provide better results than single agent 
treatment [145,146]. Combined EGFR and IGF-1R inhibition has shown benefit in 
overcoming resistance to radiotherapy in prostate cancer [147]. In vitro and animal 
studies[94] have shown that combined IGF-1R and EGFR inhibition causes a more 
significant reduction in cell survival than either agent alone in HNSCC cells [148,149]. 
IGF-1R inhibition using a monoclonal antibody in combination with Gefitinib (EGFR 
inhibitor) has been found to overcome initial treatment resistance and prevent tumour 
recurrence in mice whilst single agent treatment does not [94]. However, in clinical 
studies of IGF-1R antibody for treatment refractory HNSCC, there has been less success 
[150]. 
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Barnes et al (2007) [148] and Slomiany et al (2007) [149] both reported improved 
efficacy in reducing HNSCC cell survival when inhibiting the EGFR and IGF-1R 
pathways. The current study also found combined EGFR and IGF-1R inhibition had a 
greater impact on basal cell survival than either agent alone, with a greater effect in 
SQ20B cells with up regulation of IGF-1R. This suggests that irradiation could induce 
greater dependence on the IGF and EGF axes.  
 
Recently Raju et al (2015) [95] compared the effects of Cetuximab and IGF-1R 
monoclonal antibody IMC-A12 on HNSCC cell viability and radiation sensitivity using 
clonogenic survival assays. They found IMC-A12 did not enhance the effects of 
cetuximab in the presence of radiation but did increase radiotherapy sensitivity in one of 
the six cell lines tested. Their study reported no treatment benefit from combined IGF-
1R and EGFR inhibition, suggesting that other RTKs and/or their downstream effector 
proteins may have compensated for the loss of EGFR and IGF-1R activity. In contrast, 
the present study found reduced cell survival with the use of EGFR receptor inhibition 
and combined EGFR and IGF-1R inhibition in repeatedly irradiated cells. 
 
The clinical impact of combined EGFR and IGF-1R inhibition remains largely untested. 
On-going trials of BIIB022 (IGF-monoclonal antibody) and IMC-A12 in 
relapsed/refractory and advanced solid tumours [96,97], and a randomized trial of 
preoperative cetuximab and/or IMC-A12 in patients with HNSCC [98] are likely to 





2.5.4 Study Limitations 
This study revealed IGF-1R up regulation in irradiated LSCC cells and suppression of 
cell survival by dual IGF-1R/EGFR inhibition in repeatedly irradiated cells. Whilst the 
results of this study are promising, they should be interpreted with caution. This is the 
first study to report on the efficacy of BI836845 in HNSCC and utilised only two cell 
lines. Whilst this has advantages in that it allows for detailed analysis of the cell lines 
and potential impact for this drug, it does limit the generality of the results. One 
advantage of this study over others is that one cell line expressed EGFR whilst the other 
did not; this is relatively uncommon in HNSCC.  This allowed comparison of the 
effects of single and combined drug inhibition in both cell types, and used early and late 
passage parental cells as controls; to our knowledge this has not been done before.  
 
We were unable to geno-typically verify SQ20B cells, and BICR18 cells displayed 
different characteristics from those previously described in the literature [151,122]. This 
meant that genetic variation may have occurred over time and the tested cells might not 
have reflected the original laryngeal tumour they were cultured from. Primary cell 
culture from current patients would be useful to overcome this.   
 
Stanton and colleagues (1994) demonstrated expression of EGFR in BICR18 cells using 
radio-iodinated ligand binding [122]. In the present study, western blotting was used to 
detect EGFR in the BICR18 cell line. The inability to detect EGFR in BICR18 cells in 
this study may have reflected the lower sensitivity of western blotting when compared 
to radio-iodinated ligand binding to detect EGFR. A different EGFR antibody or 
alternative technique for detection might have provided different results. It is also 
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possible that the ligand used by Stanton and colleagues may have bound to something 
other than EGFR, providing a false positive result.  
 
Interestingly, Stanton and colleagues cultured BICR18 cells on lethally irradiated 
NIH3T3 feeder cell layers; this was not performed in the present study. The relative 
difference in EGFR expression and growth in the absence of lethally irradiated NIH3T3 
feeder cell layers may have contributed to or represented an epigenetic change in the 
cell line, a phenomenon known to occur during cell culture over a prolonged time[152].  
 
More recently Li et al (2014) described BICR18 as having mutations in the PI3K 
signalling pathway[153]. It is plausible that this might have led to decreased reliance on 
RTK signalling and hence down regulation of EGFR or reliance on signalling via an 
alternative RTK. 
 
Further analyses to detect EGFR in the BICR18 cell line might have included 
quantitative real time polymerase chain reaction (qRT-PCR) for EGFR RNA. This 
highly sensitive technique would have allowed for the detection of low levels of EGFR 
otherwise undetected by western blotting. An alternative approach might have been to 
treat cells with 5-azacitidine (a chemical analogue of the nucleoside cytosine), to 
demethylate genomic DNA to determine whether this would allow re-expression of an 
epigenetically silenced EGFR gene, followed by repeat western blotting.  
 
Overall, the inability to detect EGFR in the BICR18 cell line (despite cell line 
verification using STR) may have represented an acquired genetic alteration in the cell 
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line over time, changes acquired during cell culture, or reflected a lack of sensitivity 
during the detection process.    
 
This study was also limited by the principles of cell culture, since conventional 2D cell 
culture models do not reflect the true growth conditions or microenvironment of 
HNSCCs. Given the heterogeneous nature of HNSCCs there are likely to be a wide 
range of cell types present within the same tumour with EGFR and IGF-1R expression 
varying between cells [154]. This issue may be addressed by future studies utilising 3D 
cell culture incorporating components of the tumour microenvironment, animal models 
and clinical trials.  
 
Drug testing on all cells was performed using triplicate technical replicates but due to 
time constraints not all the results were repeated. The effects of drug treatment on 
irradiated cells should ideally be performed three times to confirm the reliability of 
results. 
 
2.5.6 Recommendations for On-going Research 
Further evaluation of the relationship between IGF-1R and EGFR expression and 
radiotherapy resistance in laryngeal cancer should assess tumour biopsies prior to and 
following radiotherapy. This will allow levels to be compared between patients that do 
and do not respond to radiotherapy to see if IGF-1R levels predict treatment response. 
This would provide in-vivo evidence for the association of IGF-1R with radiotherapy 
resistance in LSCC. The key issue of whether radioresistance could then be overcome 
by using IGF-1R or EGFR inhibitors however would still remain.  
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Combined IGF-1R and EGFR inhibition has shown benefit in limiting the survival of 
LSSCC cells as evidenced by the present study (Figure 2-12b, 2-13a). This 
combination could have a role as neo-adjuvant chemotherapy in the clinical setting, by 
reducing tumour bulk prior to radical treatment. Preclinical in vivo and clinical trials 
will be needed to evaluate this potential.  
 
IGF-1R and EGFR combined inhibition has failed to result in increased radio-
sensitization of HNSCCs. A better appreciation of the interaction between these two 
receptors and other potential contributing RTKs is necessary. Microarray analysis 
comparing parental and irradiated or relatively radio-resistant cell lines may provide 
further information about other contributing factors.  
 
2.6 Conclusions: 
Radiotherapy is frequently offered as first line treatment for early LSCC. At present we 
are unable to predict the patients most likely to benefit from this treatment. This study 
aimed to evaluate the role of IGF-1R in radiotherapy resistant laryngeal cancer cells. 
Using repeated irradiation it was possible to induce a radiotherapy resistant phenotype 
in one of two cell lines, which expressed higher levels of IGF-1R. This may be 
clinically relevant given data presented in the previous chapter, in which tumours with 
higher levels of IGF-1R appeared to be more resistant to radiotherapy. Furthermore, 
evidence of receptor ‘cross-talk’ was identified between EGFR and IGF-1R; this could 
contribute to treatment resistance to EGFR inhibitors in HNSCC.  
 
In summary, combined EGFR and IGF-1R inhibition limited cell survival in repeatedly 
irradiated LSCC cell lines, suggesting induced dependence. However, there was no 
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enhancement of the effects of radiotherapy. There is a need for further investigation into 
the interaction between these two receptors and other RTKs that might play a role in 
radiotherapy resistant HNSCC. Future studies should focus on the analysis of patient 
tissue pre and post radiotherapy and the evaluation of drugs targeting alternative 
components of the IGF-1R/EGFR axes, and additional signalling cascades in an attempt 





















Chapter 3: Current and Future Techniques for Human Papilloma Virus (HPV) 
Testing in Oropharyngeal Squamous Cell Carcinoma 
 
This chapter is based on a recently published peer review article: 
Qureishi A, Mawby T, Fraser L, Shah KA, Møller H, Winter S (2017) Current and 
Future Techniques for human papilloma virus (HPV) Testing in Oropharyngeal 
Squamous Cell Carcinoma.  




















Despite a reduction in smoking and alcohol consumption, the incidence of 
oropharyngeal squamous cell carcinoma (OPSCC) is rising. This is attributed to human 
papilloma virus (HPV) infection and screening for HPV is now recommended in all 
cases of OPSCC. Despite a variety of clinically available tests and new non-invasive 
test strategies there is no consensus on which technique is best. This review reports on 
current techniques for HPV detection in OPSCC and the clinical applicability of 
emerging techniques.  
 
Literature searches of Medline, Embase and clinicaltrials.gov using the search terms 
‘head and neck neoplasms’, ‘squamous cell carcinoma’ and ‘HPV testing’ were 
performed. 45 studies were identified and included.   
 
p16 immunohistochemistry (IHC), HPV DNA in-situ hybridization (ISH) and HPV 
polymerase chain reaction (PCR) are the commonest tests to determine HPV status. p16 
IHC and HPV DNA PCR are highly sensitive whilst HPV DNA ISH is more specific, 
these techniques conventionally utilize surgical biopsies. New tests using PCR to screen 
fine needle aspirates, saliva, brush cytology and serum for HPV are promising but have 
variable sensitivity and specificity. These non-invasive samples avoid the morbidity of 
surgical biopsies and need for tissue blocks; their clinical role in screening and 
surveillance remains largely untested. Further work is needed to validate these tests and 






Despite a reduction in smoking and alcohol consumption, the UK incidence of 
oropharyngeal squamous cell carcinoma (OPSCC) doubled from 1990 to 2006 and 
again from 2006 to 2010 [155]. This increase is mirrored worldwide and is attributed to 
human papilloma virus (HPV) associated OPSCC. HPV positive (HPV+ve) OPSCC is 
set to overtake the incidence of HPV associated cervical cancer by 2020 and is a major 
health epidemic in the western world[21]. HPV is a common infection with a 
prevalence of 7%. High-risk sub-types e.g. 16 and 18 are responsible for HPV +ve 
OPSCC and are present in 1% of the population [156].  
 
Ang et al 2010 [157] demonstrated that the prognosis and response to treatment for 
HPV negative (HPV-ve) OPSCC was different to HPV+ve disease. HPV+ve OPSCC 
affects younger non-smoking individuals with high-risk sexual practices. Nodal 
metastases are more frequent with patients tending to have a higher N stage at 
presentation [158]. The presence of HPV in OPSCC can predict prognosis, guide 
treatment decisions and determine suitability for entry into de-escalation clinical trials 
aimed at improving long term quality of life [24]. Local-regional treatment failure and 5 
year survival is reported at 13% and 82% for HPV+ve OPSCC whilst it is 42% and 35% 
in HPV negative (-ve) disease [23].  
 
HPV is the only utilised biomarker for patients with head and neck squamous cell 
carcinoma (HNSCC) but is only clinically useful for patients with OPSCC. HPV testing 
on surgically obtained biopsies is considered the standard of care for patients with 
OPSCC and is recommended by NICE [159]. Despite this UK and US head and neck 
cancer departments only test HPV in 79% and 67% of cases routinely [160], the main 
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reasons for not testing are cost, lack of clinical relevance and time constraints [161]. 
Concerns over individual clinician knowledge regarding indications for HPV testing 
have been raised with one US centre reporting clinically inappropriate requests for HPV 
testing in 77% of cases [162].   
 
The need for HPV testing when treating patients with OPSCC is well established.  The 
ideal test would be non-invasive, economical, of low complexity and easily 
incorporated into routine clinical practise. Such a test could form part of screening and 
monitoring programmes for OPSCC and shorten time to diagnosis and treatment, 
improve patient satisfaction and overall morbidity and mortality. At present there is no 
consensus on HPV testing in OPSCC with various methods described [158]. Clinical 
features including cancer stage, site, tumour differentiation, presence of cystic 
metastasis, age, race and smoking status do not accurately predict HPV status and so 
specific clinical testing is required [163].  
 
3.2 Aims: 
This review aims to help practising head and neck surgeons understand the techniques 
available for detecting HPV in OPSCC (Table 3-1), their relative advantages, 
disadvantages (Table 3-2) and clinical applicability to non-invasive ‘liquid biopsies’ 
(Table 3-3). It is hoped this information may help guide clinical decisions for future 
testing of HPV in OPSCC and increase compliance with national guidelines.  
 
3.3 Methods: 
A search of available literature was conducted on 28 August 2016 using Medline, 
Embase and clinicaltrials.gov from 1996-2016. Search terms were combinations of 
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‘head and neck neoplasms’, ‘squamous cell carcinoma’ and ‘HPV testing’.  
 
A total of 343 articles were identified, after abstract, article and reference review a total 
of 45 studies were included in this review.  
 
3.4 Results:  
The most commonly utilised techniques for HPV testing in OPSCC are p16 
immunohistochemistry (IHC) (recommended by NICE [159]), polymerase chain 
reaction (PCR) and DNA in situ hybridisation (ISH) (although other techniques have 
been described) their sensitivity and specificity is described in Table 3-4. Besides 
sensitivity and specificity each test differs in availability, expertise required, cost and 
time which has resulted in uncertainty as to which test or combination of tests should 
form the clinical standard [159].  
 
HPV testing is typically performed on formalin-fixed paraffin embedded (FFPE) tissue 
blocks although some authors have described their use on fine needle aspirates (FNA), 
saliva, brush cytology and serum/plasma.  
 
3.4.1 Routine Histology 
HPV+ve OPSCC has a characteristic appearance on routine haematoxylin and eosin 
staining. Arising from tonsillar crypt epithelium the cells are small with indistinct 
borders, generally round/oval nuclei, high levels of mitosis, and variable necrosis. 
Keratinisation is often focal and tumours predominantly non-keratinising [158,164]. 
HPV+ve OPSCC’s tend to invade as sheets, lobules or ribbons of cells in the absence of 
strong desmoplastic stromal reaction [164]. Some authors have described these 
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characteristic features as 99% specific for HPV infection [165]. A small proportion of 
keratinizing OPSCC’s however, are HPV+ve and so histology alone cannot be relied 
upon to make an accurate diagnosis of HPV infection.  
 
3.4.2 Southern Blotting 
Southern blotting is an established technique for detecting HPV DNA, enzymes are 
used to ‘digest’ target DNA from fresh frozen samples before being separated using gel 
electrophoresis and transferred to a membrane. Target proteins are hybridized with 
cloned HPV genomic probes before detection. Technical complexities and an inability 
to utilise FFPE tissue samples make this technique impractical in the clinical setting 
[166].  
 
3.4.3 p16 Immunohistochemistry (IHC) 
IHC typically utilizes antibody mediated staining of tumour samples taken from FFPE 
tissue blocks to allow a pathologist to determine the relative abundance and intensity of 
a protein. The oncogenic HPV protein E7 binds and inactivates retinoblastoma tumour 
suppressor gene (pRb) resulting in decreased pRb and Cyclin D1 and increased p16 
expression [167]. p16 is considered a surrogate marker of transcriptionally active HPV 
infection. Although interpretation of IHC is subjective only strong staining is taken to 
indicate positivity. Studies have reported 97% agreement between pathologists in 
interpreting results [168].  
 
p16 expression is considered by some as the most reliable prognostic marker for 
OPSCC and is an independent predictor of survival  although this is not always the case 
[169]. p16 has high sensitivity for HPV (94%) [170], low cost and is readily available 
	 124	
and interpretable (when signal intensity is high). These desirable features have led to 
p16 IHC being commonly adopted as a stand alone technique for HPV detection in 
clinical and research settings and is currently recommended for all cases of OPSCC in 
the UK.  
 
Two arguments have emerged against isolated p16 testing for determining HPV status 
in OPSCC. The first is limited reliability of interpretation when staining is weak or 
equivocal (<5% of cases [168]). Current UK guidelines recommend >70% staining to 
confirm p16 positivity[159]. When staining is lower a supplementary test is often 
required which may not necessarily be available in all laboratories. Whilst there is 
evidence to support HPV positivity with diffuse relatively weak p16 staining the 
associated subjectivity makes the test unreliable in this context [171].  
 
The second relates to the specificity of p16 testing, some authors have reported up to 
20% of p16-positive OPSCC’s to be HPV-ve [169]. In this context it is thought that p16 
is elevated by non-virus related alterations. A recent meta-analysis of 25 studies has 
confirmed a statistically significant number of false positives with p16 IHC alone when 
compared to p16 IHC and an additional test for HPV DNA/RNA [169]. The authors 
advocated that p16 testing should be supplemented with an additional test (either PCR 
or DNA/RNA ISH) to confirm the presence of HPV.  
 
If HPV status is required to make treatment decisions in the context of de-escalation 
treatment or new molecularly targeted therapies, in the worst-case scenario p16 alone 
could result in 1 in 5 patients receiving clinically inadequate treatment. With the 
availability of additional tests to confirm HPV DNA these risks can be avoided.  
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3.4.4 DNA in-situ Hybridisation (ISH) 
In situ hybridisation is a technique that amplifies signals on molecular probes, which 
specifically bind to HPV DNA. There are readily available probes for the detection of 
all known HPV strains. FFPE tissue can be analysed for high-risk HPV sub-types using 
an automated platform and viewed with conventional light microscopy. This technique 
is frequently available in modern pathology laboratories. DNA ISH allows for 
differential detection of nuclear and diffuse staining patterns providing a histological 
context for HPV within tumour cells.  
 
DNA ISH is an excellent clinically available test for confirming the presence of 
integrated HPV in OPSCC. Studies have shown 99% concordance between HPV 
detection in E6/E7 mRNA and HPV DNA ISH [172].  
 
DNA ISH could be the ‘clinically viable gold standard’ test for HPV detection in 
OPSCC given its superior specificity of 88% compared to 82% with p16 IHC[170]. The 
test however has a low sensitivity particularly when HPV DNA copy numbers in 
tumour tissue are low. DNA ISH also has a lower sensitivity of 88% compared to 94% 
in p16 IHC [170]. Furthermore as DNA ISH detects DNA and not mRNA it does not 
confirm transcriptional activity, it is more expensive than p16 IHC and has an 11% 
reported inter-observer variability [168]. 
 
3.4.5 RNA in-situ Hybridisation (ISH) 
RNA ISH is superior to DNA ISH as it confirms the presence of transcriptionally active 
HPV.  Even when copy numbers are low translocation amplifies the signal making 
RNA detection easier [172]. RNA ISH is promising as it identifies HPV driven cancers 
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in a single test, avoids risks of contamination (as seen in PCR), utilises FFPE tissue 
samples and has easily interpretable results[173]. RNA ISH is more sensitive and 
specific than DNA ISH in detecting HPV in OPSCC (97% and 93% vs. 88% and 88%) 
and correlates strongly with p16 expression [170].  
 
RNA ISH testing however is not available on an automated platform and is considered 
too laborious for routine use [174]. This could explain why there are relatively few 
studies of RNA ISH for HPV in OPSCC and why the technique is not yet approved for 
clinical use.  
 
3.4.6 Polymerase Chain Reaction (PCR) 
PCR is a technique used to amplify signal from mRNA or DNA by several orders of 
magnitude to detect target DNA using pre-specified primers. It is the most widely 
utilised tool for detecting and genotyping HPV.  
 
Sustained and persistent high-risk HPV E6/E7 viral oncogene expression drives the 
HPV-associated malignant phenotype. Detection of E6/E7 mRNA by reverse 
transcriptase PCR of E6/7 mRNA transcripts indicates the presence of transcriptionally 
active HPV, the “gold standard” for HPV testing [175]. Until recently this required the 
use of fresh frozen tissue but is now possible in FFPE samples, currently this is almost 
exclusively used in a research setting [172]. 
 
PCR to detect HPV DNA in FFPE is relatively easy to conduct, highly sensitive, cost 
effective and widely available. There are a variety of commercially available assays, 
with varying performance [176]. The highly sensitive nature of the test means that 
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previously amplified material can contaminate negative specimens and it is not always 
possible to tell if the DNA detected relates to the tumour cells or surrounding normal 
tissue. The reported sensitivity and specificity for this test is 97% and 87%, respectively 
[170].  
 
Besides its use in tissue samples, PCR has been used to assess the presence of HPV in 
saliva, fine needle aspirates and serum plasma. 
 
3.4.7 Combination Testing  
Combining tests for HPV may improve the accuracy of results and two-step diagnostic 
algorithms have been described that include p16 IHC followed by PCR for HPV DNA 
or p16 IHC followed by HPV DNA ISH. As an initial screen p16 positivity (which has 
high sensitivity) indicates the presence and transcriptional activity of HPV which can be 
confirmed as originating from the tumour by DNA ISH (greater specificity) [166]. The 
first algorithm has been validated in FPPE tissue against the gold standard of PCR for 
E6/7 mRNA whilst the second more practical combination has been used in large 
epidemiology studies and clinical trials and is validated as a prognostic marker.  
 
To overcome conflicting results between two tests Thavaraj et al [168] described a 
three-step technique of p16 IHC, HPV ISH and PCR alongside consensus reporting for 
ISH to improve molecular classification of tumours. In this algorithm PCR was used in 
cases where the sample was p16 positive but DNA ISH negative. PCR confirmed the 
presence of HPV DNA allowing 98% of samples to be described as HPV+ve or -ve.  
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Schache et al [170,177] compared the relative diagnostic accuracy of single and 
combined HPV tests on FFPE tissue in 108 cases of OPSCC. They compared p16 IHC 
and HPV ISH, p16 IHC and DNA PCR and p16 IHC and RNA ISH to each test 
individually reporting combined test sensitivities of 89%, 97% and 93% and 
specificities of 90%, 95% and 100%. Combined tests demonstrated improved diagnostic 
accuracy for HPV detection when compared to each test in isolation. 
 
Whilst combination testing may improve diagnostic accuracy whereby one test 
compensates for the weaknesses of another it is resource intense and a single test would 
be preferable. In the same study Schache et al [170,177] showed that RNAscope (RNA 
ISH) had 94% sensitivity and 100% specificity, raising the possibility for single test 
algorithms to eventually provide the solution to this diagnostic problem.  
 
3.4.8 Fine Needle Aspiration (FNA) 
Fine needle aspirates are routinely utilised in HNSCC diagnosis and in some patients 
represent the only available diagnostic material. DNA ISH, PCR and p16 IHC can all be 
used to determine the HPV status from cancer cells obtained by FNA when cellblocks 
are prepared from aspirated material. At present there is no consensus on HPV testing of 
FNA samples.  
 
Despite concerns regarding potential subjective interpretation particularly with low cell 
numbers, HPV DNA ISH on FNAs constructed as cellblocks from patients with OPSCC 
may prove useful. Begum et al [178] detected HPV16 in 53% of metastatic OPSCCs but 
not in FNAs from other head and neck tumour sites.  
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Others have applied these detection strategies to ethanol fixed smears of fine needle 
aspirates, avoiding the need for cell blocks[179]. Before clinical implementation 
prospective large-scale diagnostic accuracy studies for DNA ISH on FNA material are 
needed.  
 
Determining the proportion of p16 staining on FNA specimens can be difficult and is 
confounded by the fact that 50% of benign branchial cysts are often p16 positive. This 
is a practical dilemma as nodal metastases from OPSCC’s and branchial cysts occur in a 
similar age group, contain squamous epithelium and when associated with 
inflammation, cytology alone cannot confirm or exclude malignancy. In these cases p16 
status is unhelpful, as it does not predict prognosis or malignant potential.  
 
Recommended thresholds for 70% p16 staining may not apply to FNAs, instead lower 
thresholds of 10% give reported sensitivity and specificity of 94% and 75% [180]. 
There is a need for further research to validate the use of p16 IHC on FNA samples in 
the context of OPSCC.  
 
Liquid based PCR assays originally developed for cervical cancer may also prove useful 
on FNA samples; these include the Hybrid Capture II, Cervista HPV HR, Roche Cobas 
and APTIMA tests. PCR on liquid samples avoids the need to create tissue blocks but 
the tests require clinical validation. Isolated tests of HPV DNA PCR on FNAs have 





3.4.9 Brush Cytology 
HPV DNA PCR on brush cytology specimens is the clinical standard for HPV DNA 
detection in cervical cancer, however this is not the case in OPSCC [182]. Despite high 
sensitivity, low cost and availability it has not gained popularity in OPSCC. Direct 
cytological examination of brushed material is of limited value as small tumours are 
confined to tonsillar crypts and may not be sampled. Also, a surface “in-situ” 
component is often lacking, reducing the utility of morphological assessment in such 
samples. 
 
Both p16 IHC and PCR have been successfully used to detect HPV using brush 
cytology. Cytological assessments may have higher levels of sensitivity and specificity 
for HPV detection when compared to similar tests on FFPE samples and can provide 
results in just a few hours.  
 
Brogile et al [183] compared the results of PCR and p16 on brush cytology specimens 
from patients with OPSCC to conventional p16/PCR tests on FFPE and reported 
sensitivity and specificity of 83% and 94%. Larger studies by Dona et al [184] of 164 
brush cytology samples and Marques et al [185] showed 90.04% and 94.7% 
concordance between cytochemical and FFPE assessment for HPV. The latter study 
however reported inadequate sampling using brushings in 45.7% of individuals; these 
results may have been affected by bias in the study design.  
 
Linxweiler et al [186] compared combined PCR for p16INK4a (a tumour suppressor 
associated with high-risk HPV) and Ki67 (a marker of high cell turnover) on cytological 
specimens to PCR on FFPE in 20 cases. Their results demonstrated 95% concordance 
	 131	
and showed the ability to recognise details of cellular morphology including 
keratinization. Overall liquid based cytology had a diagnostic sensitivity of 98% and 
100% for diagnosing HNSCC. The results of cytological assessment using brushings are 
promising for detecting HPV and is an area requiring greater attention.  
 
3.4.10 Saliva 
Testing bodily fluids from an infected area for the presence of HPV is an established 
concept. Recent meta-analyses of urinary tests as opposed to cervical smears for 
cervical cancer screening have reported sensitivity and specificity of 73% and 98% 
[187].  
 
A saliva test that is non-invasive, relatively inexpensive, without side effects and taken 
at the point of first patient contact could allow for the HPV status of patients to be 
established much earlier. If proven successful, salivary testing for HPV could form a 
routine part of screening and risk stratification in patients suspected of OPSCC. It may 
also have a role in monitoring patients post treatment for signs of recurrence. Salivary 
testing would avoid the need to create tissue blocks required for current techniques that 
are costly and time consuming. One study has estimated a potential cost saving of $365 
per patient [188]. The potential for saliva testing for HPV has led to increased media 
attention and speculation on its use in national screening programmes [189].  
 
HPV is readily detected in the saliva of individuals and saliva testing has been used 
extensively as part of screening programmes in non-cancer patients. Levels appear to be 
higher in those that smoke, drink alcohol in excess and engage in high-risk sexual 
activities [190].  
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Saliva testing for HPV infection in OPSCC patients has been successfully trialled in 
HNSCC patients; high-risk HPV types can reliably be detected in the saliva of patients 
with HNSCC and could be used to predict the HPV status of OPSCC.  	
The sensitivity of salivary testing has been questioned with some authors reporting an 
inability to detect HPV from oral rinse specimens in patients with known HPV+ve 
OPSCC[191]. It is thought that the origin of HPV +ve cells may effect the specificity of 
tests on saliva as HPV could be detected from infection within non-tumour tissue or be 
difficult to detect with lower tumour stage [166]. Wang et al [192] showed that saliva 
was inferior to plasma when testing for HPV in patients with OPSCC; they detected 
HPV in 40% of their salivary specimens and 86% of their plasma specimens.  
 
There are a number of commercially available liquid assay tests that could be used to 
test saliva but there is a need for their validation in clinical practice. These tests have 
shown promise with FNA samples [193] but need to be assessed with saliva. Kerr et al 
[194] recently demonstrated 100% sensitivity and 86% specificity when using the PCR 
Roche Cobas 4800 test in comparison to HPV DNA ISH. Whilst Ahn et al [195] 
reported salivary HPV testing in combination with plasma testing could reliably predict 
HPV status and recurrence in OPSCC with >90% specificity and 69.5% sensitivity.  
 
Saliva testing for HPV is a promising area for research and may have a role in 
diagnosing and monitoring patents with OPSCC. There is a need for prospective 
adequately powered diagnostic accuracy studies comparing the efficacy of salivary tests 
to the clinical standards of p16 IHC, DNA ISH and HPV DNA PCR on FFPE in 
patients with OPSCC before salivary testing forms a part of routine clinical practise.   	
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3.4.11 Serum Antibodies / DNA  
Serological assays have the potential to identify HPV through antibody detection, 
however infections outside the primary OPSCC could influence the result. The findings 
of a large study comparing serum samples from 292 HNSCC patients to 1568 matched 
controls contradicted this hypothesis. The group used ELISA to detect L1 and L2 
proteins (associated with high-risk HPV types 16, 18 and 33) amongst healthy 
individuals and those with head and neck cancer and found these to be largely 
attributable to infection within tumour. The odds ratio for detecting HPV for HPV+ve 
tumours was 37.5 compared to 2.1 for HPV-ve tumours [196].  
 
Anti E6/E7 antibodies have been detected in the serum of HNSCC patients, these 
findings are thought to represent active HPV driven transformation of HNSCC as their 
detection in non HNSCC patients is rare [166]. In fact if evidence from serum testing 
for cervical cancer is to be applied to OPSCC, anti-E6/7 antibody detection post 
treatment may be a useful prognostic marker.  
 
For nasopharyngeal carcinoma the presence of plasma Ebstein-Barr Virus (EBV) DNA 
is associated with relapse or persistent tumour and can be measured as part of 
surveillance, similar principles could be applied to HPV+ve OPSCC. Although large 
prospective trials and optimization is needed, HPV DNA has successfully been detected 






3.5 Discussion and Conclusions: 
HPV testing for OPSCC is complex with various techniques described using FFPE 
tissue and ‘liquid biopsies’ e.g. saliva, brush cytology, FNA and serum.  
 
Current evidence suggests that conventional p16 IHC is useful as a screening tool for 
determining HPV status in FFPE samples from tumour biopsies and should be 
considered the first line test in all cases of OPSCC. Given the findings of a recent meta-
analysis there is evidence to support additional testing using a technique with greater 
specificity e.g. HPV DNA ISH or PCR [169].   
 
There is a need for a single modality test to increase widespread adoption and limit 
costs. Further validation of RNA ISH may prove useful in providing this desirable 
solution.  
 
Non-invasive testing for HPV in cervical cancer is now a reality and it is hoped that the 
techniques utilised here may be transferred to HPV testing in OPSCC. Whilst brush 
cytology, saliva and serum have proven effective in determining HPV status there are 
no large prospective clinical trials assessing their clinical effectiveness. These 
techniques should be assessed independently and in combination for their clinical 
effectiveness at determining HPV in OPSCC to avoid the need for invasive tissue 
biopsies and creation of tissue blocks. Clinical validation and optimisation of these tests 
may lead to ‘liquid biopsies’ being useful in screening, diagnosis and monitoring of 
HPV+ve OPSCC.   	
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Table 3-1: Current techniques for HPV Testing in OPSCC and the tissue samples to 















Routine	Histology	 ✓ ✗ ✗ ✗ ✗ 
Southern	Blotting	 ✓ ✗ ✗ ✗ ✗ 
p16	IHC	 ✓ ✓ ✓ ✗ ✗ 
DNA/RNA	ISH	 ✓ ✓ ✗ ✗ ✗ 
PCR	E6/E7	mRNA	 ✓ ✗ ✗ ✗ ✗ 
PCR	HPV	DNA	 ✓ ✓ ✓ ✓ ✓ 
HPV	antigen	detection	 ✗ ✗ ✗ ✗ ✓ 
	 	 	 	 	 	Key:	
	 	 	 	 	✓ successfully	applied 
	 	 	 	 	✗ not	applicable 
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Table 3-2: HPV Testing for OPSCC – Advantages and Disadvantages of Utilised 




























































Table 3-4: Reported Sensitivity and Specificity of HPV Testing in OPSCC  


























Chapter 4: Saliva Testing for HPV in Oropharyngeal Squamous Cell 




New cases of oropharyngeal squamous cell carcinoma (OPSCC) are routinely tested for 
HPV. HPV in saliva can be detected with PCR, but its clinical applicability in the 
context of OPSCC remains unknown.  
Methods 
Forty-six consecutive patients diagnosed with OPSCC had pre-treatment saliva 
specimens collected. PCR for HPV on saliva was compared to p16 IHC and HPV DNA 
in-situ hybridisation (ISH) on surgical biopsies.  
 
Results 
The sensitivity and specificity of saliva testing when compared to the reference test of 
p16 IHC and HPV DNA ISH was 72.2% and 90% and positive and negative predictive 
values were 96.3% and 47.4%. There were no adverse events. Time from last meal, 
smoking, alcohol drinking and physical exercise did not impact on results.  
 
Conclusions 
Saliva testing is a promising test to detect HPV in patients with OPSCC. A positive 
result could avoid the need for surgical biopsies, thereby reducing costs, patient 
morbidity, and expedite treatment.  
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4.1 Background:  
Oropharyngeal squamous cell carcinoma (OPSCC) which affects the tonsils and tongue 
base is traditionally associated with excess alcohol consumption and smoking. Despite a 
reduction in smoking and alcohol consumption, the UK incidence is rising 
exponentially [8]. The increase is mirrored in many developed countries [197], with 
approximately 63,000 new cases of OPSCC reported annually [198]. The majority are 
now attributed to HPV infection (HPV+ve) [197]. A worldwide meta-analysis has 
shown that HPV associated OPSCC has increased from 40.5% before 2000 to 72.2% 
after 2005 [155]. HPV+ve OPSCC is considered a major health epidemic in the western 
world [22]. 
 
HPV detection is emerging as a biomarker for patients with OPSCC. The presence of 
HPV in OPSCC can predict prognosis and determine suitability for entry into de-
escalation clinical trials aimed at improving long-term quality of life [24,199]. In fact, 
HPV+ve and HPV-ve OPSCC are staged separately in the latest edition of the AJCC 
cancer-staging manual [200]. Whilst current treatments are not based on HPV status 
(outside of clinical trials), the new staging system is likely to have an impact.  
 
HPV testing using p16 immunohistochemistry (IHC) on surgical or core biopsies is 
considered the standard of care for patients with OPSCC, and is recommended in all 
patients by the UK National Institute for Health and Care Excellence (NICE) [159]. p16 
IHC is also the standard of care utilised by the AJCC in determining the presence of 
HPV in patients with OPSCC [200].  Other techniques for HPV testing including the 
sensitivity and specificity of these tests are described in Table 4-1.  
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Table 4.1:  Sensitivity and specificity of clinically available tests for HPV in OPSCC 
(Schache et al 2011) [170]. Test	 Sensitivity	 Specificity	P16	IHC	 94-100%	 79-82%	PCR	 97%	 87%	DNA	ISH	 89%	 89%	
 
HPV testing for OPSCC is typically performed on surgically obtained biopsies 
performed under general anaesthesia or on core biopsies of suspected lymph node 
metastasis obtained under ultrasound guidance. These investigations have associated 
costs and risks including pain, bleeding, infection, dental injury, oesophageal 
perforation and rarely airway compromise. The procedures can result in delays to the 
patient pathway particularly when a diagnosis of squamous cell carcinoma is first made 
with fine needle aspiration cytology (FNAC). In these cases a supplementary surgical or 
core biopsy is needed from the primary site or nodal metastasis to confirm p16 status. 
With existing pressures on cancer diagnostic services [201], the process from initial 
presentation to establishing the HPV status on a biopsy of a patient with OPSCC may 
take weeks.  
 
HPV is detectable in the saliva of patients with OPSCC using PCR. This non-invasive, 
relatively inexpensive test, without side effects and taken at the point of first patient 
contact could allow for the HPV status of patients to be established much earlier. 
Salivary HPV testing has the potential to mitigate the need for invasive biopsies 
performed solely for the purpose of HPV detection, and could form a routine part of 
screening and risk stratification in patients suspected of OPSCC. To our knowledge, 
there is no prospective diagnostic accuracy study directly comparing the efficacy of oral 
rinse testing to the clinically accepted standards of p16 IHC and DNA ISH in patients 
with OPSCC.   
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4.2 Aims:  
The aim of this study was to determine the sensitivity and specificity of oral rinse (OR) 
testing for HPV in patients with OPSCC.  
 
4.3 Methods: 
A prospective diagnostic accuracy study estimating the sensitivity and specificity of oral 
rinse testing using PCR for HPV to p16 IHC and DNA ISH in patients with OPSCC 
was conducted.  The study flow diagram is shown in Figure 4-1.   Both QUADAS-2 
[202] and STARD criteria [203] were adopted. Ethical approval was sought in 

















Figure 4-1: Study Flow Diagram – Oral rinse testing for HPV in OPSCC 		
	
 





















Between September 2015 and June 2016, sixty-three patients were referred to the 
Oxford University Hospitals (OUH) Head and Neck Cancer Service with suspected 
OPSCC. Consecutive adult patients (aged >18) with mental capacity and suspected 
OPSCC were invited to participate. All patients met initial inclusion criteria, one patient 
declined consent. Oral rinse (OR) specimens and demographic data were collected from 
the 62 consenting patients prior to commencing diagnostic assessment and cancer 
treatment. 47 patients were subsequently confirmed to have a diagnosis of OPSCC and 
were included in this study. 
 
A standard operating procedure was developed whereby patients were asked to ‘gargle’ 
10mls of sterile sodium chloride solution for 20-30 seconds. This was collected in a 
sterile universal container and stored within 2 hours of collection at -80°C. OPSCC 
tumour biopsies were performed under general anaesthesia and formalin fixed, paraffin 
embedded tissue was assessed for routine diagnostic histopathology. Immunostaining 
for p16 was performed on all cases and confirmatory HPV DNA ISH on twenty-nine. 
HPV DNA ISH was performed when felt to be of clinical value, this was at the 
discretion of the reporting Consultant Head and Neck pathologist.  
 
p16 IHC was considered positive when >70% of cells showed strong nuclear and/or 
cytoplasmic staining [159].  HPV DNA ISH was carried out using the Ventana 
INFORM HPV III Family 16 Probe (B) (MDCI Ltd, West Sussex UK). The probe 
cocktail has demonstrated affinity to the following genotypes: 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, and 66. 
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The index test (Linear Array HPV Genotyping Test Kit – Roche ©) was performed by 
the OUH Molecular Diagnostics Department in accordance with the manufacturers 
instructions on all 47 samples. HPV DNA was extracted from each OR sample by 
lysing cells in denaturing conditions at elevated temperatures.  PCR amplification for 37 
different HPV subtypes was performed using the provided ‘master mix’. Hybridization 
was used to label oligonucleotide probes before using a Streptavidin-Horseradish 
peroxidase conjugate to identify HPV status and sub-type using the Linear Array HPV 
Genotyping Test Reference Guide. Suitable controls were used at each stage of the 
process. There was one OR test failure meaning that 46 of 47 eligible patients were 
included in the final analysis. Both reference and index tests were conducted by 
qualified technicians blinded to the clinical presentation and results.  
 
When the results of p16 IHC and DNA ISH were combined to determine HPV status a 
sample was considered positive if it was either p16 IHC positive with no HPV DNA 
ISH test, p16 IHC positive and HPV DNA ISH positive or p16 IHC negative and DNA 
ISH positive. A sample was considered HPV negative if it was p16 IHC negative with 
no HPV DNA ISH test, p16 IHC negative and HPV DNA ISH negative or p16 IHC 
positive and DNA ISH negative.  
 
Statistical Analysis 
A power calculation was conducted using Stata 13 (StataCorp LP) software to 
determine a sample size of 45 for 80% power to determine results with a standard error 
of 5% and 10% confidence intervals. All statistical analyses were pre-determined and 
performed using Prism 6 for Mac OS X (© 1994-2015 GraphPad Software, Inc). The 
demographic differences in the patient population based on p16 IHC and ‘true vs. false’ 
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OR results were analysed using a Fisher’s exact test when categorical values were less 
than 5 and a Chi2 test when they were greater than 5 or when there were more than 2 
categories. A result was considered significant when p was <0.05. Sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) and 
their 95% confidence intervals were calculated.  
 
4.4 Results: 
The mean age of participants was 58.8 years (range; 37-80) (see Table 4-2). There were 
35 males (76.1%) and 11 females (23.9%); all patients were of Caucasian descent. The 
mean alcohol consumption was 19.8 units per week; there were 34 (73.9%) current or 
ex tobacco smokers with an average 23.2 pack year (range; 1-50) smoking history. The 
majority of patients presented with T1/2 tumours (71.7%) with advanced local 
metastases in 78.3% (N2/3). One patient (2.2%) had distant metastases. Five patients 























Table 4-2: Patient Demographics and Tumour Characteristics by p16 Status 
	







Male	 35	(76.1)	 25	(73.5)	 10	(83.3)	 0.70	
Female	 11(23.9)	 9	(26.5)	 2	(16.7)	 	
Age,	(years)	 	 	 	 	
>60	 18	(39.1)	 12	(35.3)	 6	(50)	 0.37	
<60	 28	(60.9)	 22	(64.7)	 6	(50)	 	
ASA	grade	 	 	 	 	
1/2	 42(91.3)	 32(94.1)	 10(83.3)	 0.28	
3/4/5	 4	(8.7)	 2(5.9)	 2(16.7)	 	
Ethnicity	 	 	 	 	
Caucasian	 46	(100)	 34	(100)	 12	(100)	 n/a	
Drinking	Status	 	 	 	 	
Nil	 6	(13)	 5	(14.7)	 1	(8.3)	 0.12	
1-21	units/week	 29	(63)	 22	(64.7)	 7	(58.3)	 	
21-40	
units/week	
7	(15.2)	 6	(17.6)	 1	(8.3)	 	
>40	units/week	 4	(8.7)	 1	(2.9)	 3	(25)	 	
Smoking	status	 	 	 	 	
Never	 12	(26.1)	 10	(29.4)	 2	(16.7)	 0.44	
Ex-smoker	 21	(45.7)	 16	(47.1)	 5	(41.7)	 	
Current	 13	(28.3)	 8	(23.5)	 5	(41.7)	 	
T	Classification	 	 	 	 	
T1/2	 33	(71.7)	 25	(73.5)	 8	(66.7)	 0.71	
T3/4	 13	(28.3)	 9	(26.5)	 4	(33.3)	 	
N	Classification	 	 	 	 	
N0/1	 10	(21.7)	 5	(14.7)	 5	(41.7)	 0.05	
N2/3	 36	(78.3)	 29	(85.3)	 7	(58.3)	 	
M	classification	 	 	 	 	
M0	 45	(97.8)	 33	(97.1)	 12	(100)	 1.00	
M1	 1	(2.2)	 1	(2.9)	 0	(0)	 	
	
Abbreviations: n/a, not applicable; ASA, American Society of Anaesthesiologists Performance Status.
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There were 34 (73.9%) p16 positive (+ve) and 12 (26.1%) p16 negative (-ve) samples. 
There were no statistically significant differences between the two groups in terms of 
age, sex, co-morbidities, alcohol consumption, smoking status, tumour size or distant 
metastases. Patients with p16+ve OPSCC presented with a higher N stage than those 
that were p16-ve  (85.3% vs. 58.3% p=0.05).  
 
4.4.1 Disease Prevalence, Sensitivities, Specificities and Predictive Values for HPV  
The patient specimens were categorised into 3 groups for analysis: those that had p16 
IHC and OR testing (n=46), those with DNA ISH and OR testing (n=29) and those that 
had p16 IHC with or without DNA ISH and OR testing (n=46). The patients and test 
















Figure 4-2: Results of HPV Testing  
A, Patients tested with p16 IHC and ‘oral rinse test (OR)’; B, Patients tested with HPV 
DNA ISH and ‘oral rinse test’; C, Patients tested with p16 IHC without or without DNA 




Abbreviations: OR, oral rinse test; +ve, positive; -ve, negative 
46	pa$ents	
34	p16	IHC	+ve	 12	p16	IHC	–ve	


















































































































































































































































































































































Using the previously described method for combined p16 IHC and DNA ISH as the 
reference test there were 36 HPV positive (78.3%) and 10 HPV negative (21.7%) 
samples. Of the 36 HPV positive samples 26 were positive and 10 negative on OR 
testing.  Out of the 10 HPV negative samples 1 was positive and 9 negative on OR 
testing. The prevalence of HPV was 78.3% (63.6%-89.1% 95% CI). The sensitivity and 
specificity of OR testing when compared to the reference test of p16 IHC with and 
without HPV DNA ISH was 72.2% (54.8%-85.8% 95% CI) and 90% (55.5%-99.8% 
95% CI) and PPV and NPV were 96.3% (81.0%-99.9% 95% CI) and 47.4% (24.5%-
71.1% 95% CI). 
 
4.4.2 Identification of HPV Sub-types 
Oral rinse testing using the Linear Array HPV Genotyping Test Kit (Roche ©) allows 
identification of up to 37 different HPV subtypes. Twenty-seven out of 46 ‘oral rinse’ 
tests were positive for HPV (see Figure 4-3). There was 1 false positive result that 
suggested the presence of HPV 16 (p16 IHC and HPV DNA ISH negative). HPV 16 
alone was detected in 21 samples (77.8%); HPV 18 alone in 1 sample (3.7%), whilst the 
remaining 5 samples (18.5%) all contained HPV 16 alongside other HPV subtypes. The 
combinations detected were HPV 16/33/35/52/58, HPV 16/31/35, HPV 16/53, HPV 












4.4.3 Evaluating Potential Confounding Factors 
To evaluate potential patient demographic, tumour or environmental factors that may 
have resulted in a false test result additional patient specific information was collected 
including time of last alcoholic drink, smoke, meal and exercise (see Table 4-4). Using 
the reference standard of combined p16 IHC and HPV DNA ISH as previously 
described there were 35 patients (76.1%) with a true positive or negative result and 11 
(23.9%) with a false positive or negative result. There was no statistically significant 
difference between the two groups in terms of age, co-morbidities, T/N/M stage, last 






























































	 	 Oral	Rinse	Test	Result	 	
	 Total	Patients,	No.(%)	N=46	
True	+ve/-ve,	No.(%)	(n=35)	 False	+ve/-ve,	No.(%)	(n=11)	 P-	Value		
Age,	(years)	 	 	 	 	
>60	 18(39.1)	 16(45.7)	 2(18.2)	 0.16	
<60	 28(60.9)	 19(54.3)	 9(81.8)	 	
ASA	 	 	 	 	
1/2	 42(91.3)	 31(88.6)	 11(100)	 0.56	
3/4/5	 4(8.7)	 4(11.4)	 0(0)	 	
T	Classification	 	 	 	 	
T1/2	 33(71.7)	 24(68.6)	 9(81.8)	 0.47	
T3/4	 13(28.3)	 11(31.4)	 2(18.2)	 	
N	Classification	 	 	 	 	
N0/1	 10(21.7)	 8(22.9)	 2(18.2)	 0.99	
N2/3	 36(78.3)	 27(77.1)	 9(81.8)	 	
M	classification	 	 	 	 	
M0	 45(97.8)	 34(97.1)	 11(100)	 0.99	
M1	 1(2.2)	 1(2.9)	 0(0)	 	
Last	Alcoholic	Drink	 	 	 	
Never	 16(34.8)	 12(34.3)	 4(36.4)	 0.82	
<	6	hours	 1(2.2)	 1(2.9)	 0(0)	 	
6-24	hours	 20(43.5)	 16(45.7)	 4(36.4)	 	
>	24	hours	 9(19.6)	 6(17.1)	 3(27.3)	 	
Last	Smoke	 	 	 	 	
Never	 34(73.9)	 26(74.3)	 8(72.7)	 0.40	
<	6	hours	 7(15.2)	 4(11.4)	 3(27.3)	 	
6-24	hours	 2(4.3)	 2(5.7)	 0(0)	 	
>	24	hours	 3(6.5)	 3(8.6)	 0(0)	 	
Last	Meal	 	 	 	 	
<	2	hours	 7(15.2)	 4(11.4)	 3(27.3)	 0.30	
2-6	hours	 25(54.3)	 21(60)	 4(36.4)	 	
>	6	hours	 14(30.4)	 10(28.6)	 4(36.4)	 	
Last	Exercise	 	 	 	 	
<	6	hours	 4(8.7)	 4(11.4)	 0(0)	 0.44	
6-24	hours	 10(21.7)	 8(22.9)	 2(18.2)	 	
>	24	hours	 32(69.6)	 23(65.7)	 9(81.8)	 	
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4.4.4 Adequacy of Samples and Adverse Events 
One (2.1%) of 47 oral rinse samples provided a non-interpretable result. The sample 
was analysed twice giving the same result. In accordance with the manufacturers 
instructions an invalid result was believed to be due to inadequate specimen collection 
which may have related to the collection of saliva, sample processing e.g. prolonged 
processing time, or the presence of inhibitors e.g. activity of enzymes. Repeat sampling 
of the same patient was recommended by the product manufacturer but not possible as 
treatment for this patient had already commenced by this stage.  
 
Whilst some patients reported that the taste of sodium chloride was unpleasant and 
some needed to repeat the test due to spillage, there were no adverse events associated 
with oral rinse testing.   
 
4.5 Discussion: 
Our study has demonstrated that OR testing using PCR to detect HPV in patients with 
OPSCC has sensitivity, specificity, positive and negative predictive values of 72.2%, 
90%, 96.3% and 47.4% respectively. Whilst the NPV is low making interpreting a 
negative result unreliable, with one sample failure and no adverse events reported this 
study demonstrates that PCR on oral rinse specimens is a viable method for determining 
HPV in OPSCC. Smoking, alcohol consumption, last meal and exercise do not appear 
to affect the accuracy of OR testing meaning that specific pre-test preparation is not 
required.  
 
Testing for HPV in OPSCC is increasingly important as HPV status can provide 
important diagnostic and prognostic information. Testing needs to be sensitive and 
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specific, reproducible and validated. There is considerable debate as to the optimum test 
for HPV [170].  The commonly described techniques of p16 IHC, HPV DNA ISH and 
PCR on tumour tissue have associated advantages and disadvantages [204]. HPV DNA 
ISH is able to demonstrate HPV integration within tumour cells, but as it detects DNA 
and not mRNA it also does not confirm transcriptional activity [204].  p16 IHC, 
although not 100% specific is emerging as a prognostic marker for OPSCC in its own 
right [205,206]. It is considered a surrogate marker of HPV transcriptional 
activity[204]. There are associated limitations, Wasylyk et al (2013) [169] reported p16 
IHC alone confirmed a significant number of false positives for HPV when compared to 
p16 IHC supplemented by either PCR or DNA/RNA ISH. PCR for HPV is highly 
sensitive; whilst this has obvious advantages it is not always possible to tell if the DNA 
detected relates to the tumour cells or surrounding normal tissue [204].  
 
OR testing offers an alternative to conventional HPV testing in OPSCC with potential 
benefits of reduced patient morbidity, shorter time to diagnosis and reduced cost. It is 
also limited by the highly sensitive nature of PCR, whereby detected HPV DNA might 
not relate to tumour tissue, and instead represent a bystander infection.   
 
The sensitivity of salivary testing however has been questioned with some authors 
reporting an inability to detect HPV from OR specimens in patients with known 
HPV+ve OPSCC [191]. Zhao et al [207] detected HPV in 50% (21 of 42 specimens) of 
salivary samples from patients with HPV+ve OPSCC using PCR. Whilst Wang et al 
[192] found that saliva was inferior to plasma when testing for HPV in patients with 
OPSCC. They detected HPV in 40% of their salivary specimens and 86% of their 
plasma specimens. Our results contradict these findings; whilst plasma testing for HPV 
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was not performed we were able to detect HPV in the saliva of HPV+ve cases in 72.2% 
of cases. This could relate to the way samples were collected, processed and stored in 
the studies.  
 
Although the results of our study, which to our knowledge is the first of its kind, are 
promising, it is important to consider the results of PCR testing for HPV using other 
non-invasive biopsies. Channir et al [181] recently utilised PCR on fine needle aspirates 
(FNAs) of patients with OPSCC reporting 94.7% sensitivity and 100% specificity 
whilst Brogile et al [183] used PCR on oropharyngeal brush cytology specimens from 
patients with OPSCC reporting sensitivity and specificity values of 83% and 94%.  
Although these results seem superior to OR testing, FNA assessment and brush 
cytology analysis have limitations. Specifically FNAs are limited by the quality of the 
sample obtained which may be operator dependant [208] whilst inadequate sampling 
from oropharyngeal brush cytology is high (45.7%) [185]. Both tests require further 
clinical validation.    
 
Unlike other diagnostic accuracy studies utilising non-invasive biopsies to determine 
HPV status in OPSCC this study was carried out prospectively using QUADAS-2 and 
STARD criteria to limit bias and mirror clinical practise. Patients were included 
consecutively, analyses predetermined and participants closely reflected those seen in 
clinical practise e.g. HPV prevalence >70%, no involuntary exclusions.  Both reference 
and OR tests were performed by qualified technicians blinded to the study objectives 
and other test results to limit bias.   
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This study was limited by the lack of E6/7mRNA testing considered the research ‘gold 
standard’ for HPV detection in OPSCC [175]. Whilst the clinical standards of p16 IHC 
and DNA ISH were utilised as reference tests all included samples did not have HPV 
DNA ISH performed. This could have introduced bias in the results and underestimated 
the specificity and negative predictive value of OR testing. Nonetheless, the reference 
test utilised represented clinically acceptable standards for HPV detection in OPSCC. 
Separate analyses were performed for p16 IHC alone and p16 IHC supplemented by 
DNA ISH when clinically indicated.  
 
4.6 Conclusions:  
Given the negative impact of delayed diagnosis and treatment, OR testing could allow 
for immediate HPV testing at the primary clinical presentation even before specialist 
consultation. The relatively high specificity and PPV and low NPV mean that a positive 
OR test could be relied upon whilst a negative test would require additional 
conventional testing. This would only apply to the population of patients suspected of 
having OPSCC, given the high prevalence of the disease (as seen in the present study 
and previously reported in the literature [199]).  
 
General practitioners could take samples from patients at the time of specialist referral 
so that HPV status could be available at the first specialist assessment. Patients 
presenting with an oropharyngeal lesion and neck nodes (as in most cases of OPSCC) 
could then have a core biopsy performed at the specialist consultation followed by 
cross-sectional imaging for staging. These results could provide the treating clinician 
with a tissue diagnosis, HPV status (if OR positive) and radiological stage. In selected 
cases, for example when a patient is deemed medically unfit for surgery, this could be 
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sufficient to plan treatment and avoid the risks and time associated with surgical 
biopsies. In select cases e.g. T1/T2 OPSCC with good mouth opening, this could also 
allow sufficient information for surgical planning in the form of transoral robotic 
resection.  
 
Given the relatively low prevalence of high risk HPV subtypes in the general population 
(1%) [156], and the fact that we are unclear as to which infections are likely to persist, 
OR testing is unlikely to have a clinical role in HPV related OPSCC screening for the 
general population. The diagnostic accuracy of this test will be too low given a 1% 
prevalence of the disease. However, in patients with HPV associated OPSCC where the 
prevalence is high, OR testing might provide an opportunity for post treatment 
monitoring of recurrence. In fact, given that the prevalence of HPV will be 100% in this 
population, the diagnostic accuracy for OR testing is likely to be even higher than 
reported in the present study.  
 
Furthermore, given that most cases of recurrence are within the first year after treatment 
[209] and the high PPV of the test in this population of patients, regular OR tests might 
provide earlier detection of recurrence. For example, patients might have a post 
treatment OR test, followed by monthly tests at their clinical follow up appointments.  
 
In theory, this would provide information prior to any repeat imaging or clinical 
examination findings. In fact, post treatment positive OR tests might suggest the 
microscopic persistence of malignant disease requiring further treatment that might 
otherwise go undetected till the disease has advanced. At present there are no post 
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treatment diagnostic techniques in practise offering this level of monitoring that are safe 
and easily administered.  
 
Overall, there is a need for large prospective studies that look not only at the diagnostic 
accuracy of HPV detection in OPSCC but also at recurrence and the role of HPV testing 
in surveillance. It may be that OR testing alone may not be sufficient and require 
combination with other non-invasive tests. Ahn et al [195] recently tested both saliva 
and serum to detect HPV in recurrent OPSCC with >90% specificity and 69.5% 
sensitivity. Future studies should compare all non-invasive diagnostic materials for 
HPV including brush cytology, FNA and serum plasma to both clinical and research 
















Chapter 5: Conclusions - Molecular Targets in Head and Neck Cancer 
Treatments for HNSCC have failed to keep pace with treatments for other solid organ 
tumours e.g. breast cancer and malignant melanoma. For breast cancer and malignant 
melanoma, personalised therapies are a reality and have demonstrated improved patient 
survival. This thesis explored some of the molecular targets described in HNSCC, 
aiming to answer specific clinical questions relating to the management of HNSCC.    
 
For early LSCC, where radiotherapy is often first line treatment, radiotherapy failure 
and the subsequent morbidity of salvage laryngectomy remain an issue. There is a 
clinical need to identify a biomarker of radiotherapy failure in LSCC. This could avoid 
the morbidity of radiotherapy and salvage laryngectomy in appropriately selected 
patients and potentially improve survival by the use of alternative primary treatments 
e.g. TLM or radiosensitizing agents e.g. RTKs.  
 
In OPSCC, HPV has shown promise as a prognostic biomarker and potential guide for 
de-escalation treatment, however controversies over the ideal method for its detection 
have arisen. HPV can be detected in tumour biopsies using a variety of techniques, 
other non-invasive sampling methods have also been described e.g. saliva. There is a 
clinical need to evaluate the diagnostic accuracy of these techniques before they are 
utilised in clinical practise.  
 
This thesis aimed to explore the role of IGF-1R as a predictor of radiotherapy resistance 




5.1 IGF-1R and Radiotherapy Resistance in Laryngeal Cancer 
To explore the potential role of IGF-1R as a marker of radiotherapy resistance in LSCC, 
tumour biopsies were collected from patients that had and had not responded to 
radiotherapy. IHC was used to compare levels of IGF-1R and EGFR between the two 
groups.  
 
The results demonstrated higher levels of IGF-1R in LSCC biopsies from patients with 
radiotherapy failure when compared to those with no kown recurrence following 
radiotherapy. They also showed rising levels of IGF-1R in patients with radiotherapy 
failure when comparing initial and post radiotherapy biopsies, suggesting an association 
between radiotherapy treatment and increased IGF-1R levels. A weak association 
between IGF-1R and EGFR levels was also noted.  
 
These results provided the basis for subsequent cell line work looking at the potential 
for IGF-1R to act as a driver of radiotherapy resistance in LSCC. Two laryngeal cancer 
cell lines were repeatedly irradiated in an attempt to create a relatively radiotherapy 
resistant phenotype. One radiotherapy resistant cell line was generated. Western blotting 
demonstrated higher levels of IGF-1R in the relatively radiotherapy resistant cell line, 
and increased IGF-1R levels following radiotherapy in the other cell lines. These results 
mirrored those seen in earlier IHC studies.  
 
In one cell line, EGFR and IGF-1R cross talk was demonstrated, EGF ligand was shown 
to activate IGF-1R. When BI836845 (IGF-ligand antibody) was given alongside EGF 
ligand in an attempt to prevent activation of IGF-1R, there was no detectable effect on 
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signalling. These results suggested the formation of an IGF-1R/EGFR complex or 
signalling via an alternative pathway e.g. G-protein coupled receptors.  
 
Drugs targeting the IGF-1R (BI836845) and EGFR (Afatinib) signalling cascades were 
tested as radio sensitizing agents, their combined use appeared to be no superior to their 
use alone. However, combined EGFR/IGF-1R inhibition appeared to have a significant 
impact on baseline cell survival when compared to each agent alone. The effect was 
greatest in previously irradiated cells with elevated IGF-1R.   
 
Whilst the results of these studies should be interpreted cautiously, given the limitations 
as previously described in each chapter, the results warrant further investigation. The 
findings suggest an association between IGF-1R levels, radiotherapy resistance and 
previous radiotherapy. Providing evidence for IGF-1R as a marker of radiotherapy 
resistance in LSCC.   
 
They also suggest a role for combined IGF-1R and EGFR inhibition as a potential 
treatment for patients with LSCC and IGF-1R overexpression. So far, drugs targeting 
RTKs e.g. Cetuximab have been limited by the development of treatment resistance [1], 
this might be due to receptor cross-talk [51], whereby one RTK compensates for the 
loss of another. Cross talk between EGFR and IGF-1R was clearly demonstrated in the 
study described and whilst combined target inhibition did not appear to prevent 
signalling, there was a significant effect on survival in cells with IGF-1R 
overexpression. These results suggest the potential for combined receptor targeting or 
targeted patient selection providing the solution to issues around treatment resistance.  
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So far only human papilloma virus (HPV) has shown promise as a biomarker for 
treatment in OPSCC [93]. There are no clinically utilised biomarkers for personalised 
therapy in LSCC. If these results are replicated in large-scale prospective studies, IGF-
1R status could help refine current treatment decisions. Much like HPV testing for 
OPSCC, IGF-1R testing could contribute to treatment decisions in LSCC. Patients with 
high IGF-1R could be offered primary surgery with radiotherapy and chemotherapy 
held in reserve. This could alter current trends towards primary radiotherapy based on 
TNM status and patient factors [30] to treatment guided by the molecular profile or 
IGF-1R status of tumours. 
 
Prospective large-scale multi-centre trials are needed to test these findings and 
determine the ‘clinically relevant’ level to define IGF-1R overexpression. There is also 
a need for further investigation into the interaction between EGFR, IGF-1R and other 
RTKs that might play a role in radiotherapy resistant HNSCC. Future studies should 
focus on the use of patient tissue pre and post radiotherapy and utilise drugs targeting 
alternative parts of the IGF-1R and EGFR signalling cascade in an attempt to 
radiosensitive laryngeal cancer cells.  
 
5.2 HPV testing in Oropharyngeal Cancer 
HPV testing for OPSCC is complex with various techniques described using FFPE 
tissue and ‘liquid biopsies’ e.g. saliva, brush cytology, FNA and serum. Despite the 
variety of available tests there is no consensus on which technique is best, although p16 
IHC on FFPE tissue is considered the clinical standard [159]. To evaluate the evidence 
behind each of the techniques available for HPV testing in OPSCC a literature review 
was performed.  
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 P16 IHC, HPV DNA ISH and HPV PCR are the commonest tests to determine HPV 
status. P16 IHC and HPV DNA PCR are highly sensitive whilst HPV DNA ISH is more 
specific; these techniques typically utilize surgical biopsies. Current evidence suggests 
that conventional p16 IHC is useful as a screening tool for determining HPV status, and 
should be considered the first line test in all cases of OPSCC. Given the findings of a 
recent meta-analysis, there is also evidence to support additional testing using a 
technique with greater specificity e.g. HPV DNA ISH or PCR [169].  There is also a 
need for a single modality test to increase widespread adoption and limit costs. RNA 
ISH has shown promise in this regard.  
 
New tests using PCR to screen fine needle aspirates, saliva, brush cytology and serum 
for HPV are promising but are yet to be validated in a clinical setting. These non-
invasive samples avoid the morbidity of surgical biopsies and need for tissue blocks; 
their clinical role in screening and surveillance remains largely untested.  
 
To answer this important clinical question, a study was designed to determine the 
diagnostic accuracy of PCR on saliva to determine HPV status in patients with OPSCC. 
The index test was compared to the reference standards of p16 IHC with HPV DNA 
ISH. The overall results demonstrated 72.2% sensitivity and 90% specificity, with 
96.3% and 47.4% positive and negative predictive values. The results were not 
influenced by pre-test meal, alcohol consumption or smoking, meaning there was no 
need for prior preparation. Given the negative impact of delayed diagnosis and 
treatment, saliva testing could allow for immediate HPV testing at the primary clinical 
presentation even before specialist consultation. The relatively high specificity and PPV 
and low NPV mean that a positive saliva test could be relied upon whilst a negative test 
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would require additional conventional testing.  
 
Clinically, this means that general practitioners could take samples from patients at the 
time of specialist referral, so that HPV status could be available at the first specialist 
assessment. This is particularly important given that the latest AJCC staging criteria for 
OPSCC is now dependant on HPV status [200].  Patients presenting with an 
oropharyngeal lesion and neck nodes (as in most cases of OPSCC) could have a core 
biopsy performed at the specialist consultation followed by cross-sectional imaging for 
staging. These results would provide the treating clinician with a tissue diagnosis, HPV 
status (if positive) and radiological stage. In selected cases, for example when a patient 
is deemed medically unfit for surgery or the patient has declined surgical treatment, this 
would be sufficient to plan treatment and avoid the risks and time associated with 
surgical biopsies. Of course, there are likely to be exceptions e.g. when there is 
insufficient tissue or when a synchronous primary is suspected.   
 
Despite the limitations of this study, the results provide evidence to support the design 










Overall, after completing this thesis, I can make the following conclusions:  
 
1.  Elevated IGF-1R appears to associate with previous radiotherapy and 
radiotherapy resistance in LSCC. Treatments accounting for IGF-1R status, or 
molecular therapies targeting this receptor, may have merit in patients whose 
tumours overexpress IGF-1R. 
 
2.  Saliva testing for HPV is a promising alternative to p16 IHC performed on 
tumour tissue. In selected patients, this might avoid the need for surgical 























AJCC American Joint Committee on Cancer 
ASA American Society of Anaesthesiologists Performance Status 
BI BI836845 
BSA Bovine Serum Albumin 
CI Confidence Interval 
CSA Clonogenic Survival Assay 
DER Dose Enhancement Ratio 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl Sulfoxide 
EBV Ebstein Barr Virus 
ECACC European Collection of Cell Cultures 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
FFPE Formalin Fixed Paraffin Embedded 
FNA Fine Needle Aspiration 
FNAC Fine Needle Aspiration Cytology 
Fr Fraction 
GPCR G Protein Coupled Receptor 
GS Goat Serum 
Gy Gray 
HNSCC Head and Neck Squamous Cell Carcinoma 
HPV Human Papilloma Virus 
IGF  Insulin Growth Factor 
IGF-1 Insulin Growth Factor Ligand 
IGF-1R Insulin Growth Factor Receptor Type 1 
IHC Immunohistochemistry 
IRS Immunoreactive Score 
ISH In-situ Hybridisation 
kDa Kilodaltons 
LSCC Laryngeal Squamous Cell Carcinoma 
MDT Multi-disciplinary Team 
MW Molecular Weight 
MW-U Mann-Whitney U test 
n/a Not Applicable 
NHEJ Non Homologous End Joining 
NICE National Institute for Health and Care Excellence 
nM nanomolar 
NPV Negative Predictive Value 
OPSCC Oropharyngeal Squamous Cell Carcinoma 
OR Oral Rinse 
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p Phosphorylated 
PBS Phosphate Buffered Saline 
PCR Polymerase chain reaction 
PPV Positive Predictive Value 
pRb Retinoblastoma Tumour Suppressor Gene 
r Pearson’s Correlation Co-efficient 
RTKs Receptor Tyrosine Kinases 
RTOG Radiation Therapy Oncology Group  
Rtx Radiotherapy 
RwR Radiothearpy without known recurrence  
SDS-PAGE SDS, Polyacrylamide Gel Electrophoresis 
SF Sample Failure 
SF50 Dose of radiotherapy to suppress cell survival to 50% of control 
cells 
SM Skimmed Milk 
STL  Salvage Total Laryngectomy 
STR Short Tandem Repeat 
TL Total Laryngectomy 
TLM Trans-oral Laser Microsurgery 
Tx Treatment 
UK United Kingdom 
US United States of America 
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